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Abstract
Depression is a common mental health comorbidity in cancer diagnoses, affecting 8-24%
of cancer patients. Despite the high prevalence of depression among cancer patients, it is
often unrecognized and untreated, thereby representing an enormous psychological
distress source among the cancer patient population. The purpose of this study was to
explore and establish the factors that predict depression screening among cancer patients
in the ambulatory care setting in the United States. The health belief model guided the
study. Secondary data from the National Ambulatory Medical Care Survey were analyzed
to evaluate the predictors of depression screening in patients diagnosed with cancer. The
logistic regression model was used to analyze the data and test whether the independent
variables predicted depression screening among cancer patients. The study result showed
a low depression screening rate of 3.8% among cancer patients. Patient age, physician
specialty, and geographic region of the physician visit were found to be statistically
significant predictors of receipt of depression screening among cancer patients attending
ambulatory care settings. However, when all of the independent variables were controlled
for in the logistic model, the gender variable was no longer a statistically significant
predictor of depression screening, thereby indicating a potential confounding effect.
Overall, the current study may contribute positively to society by stimulating new
approaches to recognizing and managing patients with comorbid conditions and
informing public debates, policy-making strategies, and screening guidelines.
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Chapter 1: Introduction to the Study
Background
Cancer continues to be one of the leading causes of death in the United States,
second only to cardiovascular disease (D’Souza et al., 2019). Comorbidity with cancer is
associated with increased cancer-specific mortality and other causes of mortality (Pule et
al., 2019). Specifically, there is abundant evidence that for cancer patients, an additional
diagnosis of mental illness, including depression, reduces survivability (Koroukian &
Sajatovic, 2017; Zhu et al., 2017). In addition to the excess cancer mortality seen in
people with depression, cancer, and depression, comorbidity prevalence also continues to
increase (Krebber et al., 2014). The literature shows considerable variation in prevalence
estimates of comorbid depression and cancer. Such estimates are partly dependent on the
methodology used to define depression and the population (Michael, 2007). Walker and
colleagues used strict eligibility criteria in selecting articles to address the limitations of
previous reviews and explore the prevalence of depression in adults with cancer. The
authors reported a prevalence of 5-16% in outpatients, 4-14% in inpatients, 4-11% in
mixed outpatient and inpatient samples, and 7-49% in palliative care (Walker et al.,
2013). Other authors have reported similar estimates (Wagner et al., 2017). However, still
other authors have reported higher prevalence rates, such as 21.5% in a Taiwanese cancer
inpatient population (Tu et al., 2014) and 56.5% in a Czechoslovakian population
(Světláková et al., 2019).
Some authors have estimated the prevalence of depression by cancer type. For
example, Margari et al. (2016) investigated depression and anxiety among lung cancer
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patients. The prevalence of depression in Margari et al.’s sample was 21.8%, and the
prevalence of anxiety was 17.9%. The authors demonstrated a statistically significant
correlation between depression and hospitalization, with hospitalized patients exhibiting
almost twice the severe depression rates compared to those not hospitalized.
Wondimagegnehu et al. (2019) conducted a cross-sectional study of 428 breast cancer
patients and reported that 1 in every 4 patients had depression.
Early detection and prompt treatment of depression symptoms among cancer
patients can reduce patients’ suffering, prevent progression to a major depressive
disorder, and improve treatment compliance (Howell et al., 2011). Although more
favorable outcomes have been documented when depression is treated, cases may go
unrecognized and untreated (Abid et al., 2018). There have been several calls to
proactively and systematically screen for depression in cancer patients (McNiff et al.,
2008; Riba et al., 2019; Wagner et al., 2013). Several screening tools for depression have
been developed, some of which have been validated for use in oncology. While screening
tools used to measure depression in patients with physical illness have generally not
demonstrated superior clinical use compared to traditional clinical interviews and mental
status examination, screening instruments can nevertheless be useful in identifying
patients in need of further assessment (PDQ Supportive and Palliative Care Editorial
Board, 2019). Screening instruments commonly used for this purpose include the
Hospital Anxiety and Depression Scale (HADS), the nine-item Patient Health
Questionnaire (PHQ-9), and the Distress Thermometer (Love et al., 2002; Spitzer et al.,
1999).
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Identifying the potential predictors of and risk factors for the development of
depression in cancer patients could facilitate the prompt identification of patients at risk
for depression. Several authors have explored such predictors. For example, Wen et al.
(2019) conducted a systematic literature review to identify the risk factors for depression
in cancer patients undergoing chemotherapy. Social support, anxiety, perceived stress,
and self-efficacy were factors that were consistently associated with depression in cancer
patients. Gender has also been shown to be a variable with a potential effect on the
diagnosis of depression. Lima et al. (2016) explored the predictor variables for depression
in 400 adult cancer outpatients attending a specialized cancer hospital. Male gender was
the only protective factor found against the development of depressive disorder. Female
gender was found to be a risk factor for both depression and anxiety disorder. Other
factors explored included previous psychiatric history and marital status, which were risk
factors for developing an anxiety disorder.
Although studies have identified predictors of depression screening among the
general adult population and adult population with chronic disease, no studies have
systematically explored predictors of depression screening among cancer patients. For
example, Bhattacharjee et al. (2018) examined national patterns of predictors and trends
in depression screening among adults without depression in the United States. The
predictors examined included year, gender, physician specialty, geographic region, and
time spent with the physician. The national-level depression screening rate was reported
as 1.4% of all adults studied, and the predictors examined were significantly associated
with depression screening.
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There is a tendency for patients with chronic physical conditions such as cancer to
use mental health services less than those without such conditions. Jolles and colleagues
(2015) studied whether the presence of chronic physical conditions was associated with
mental health service use for individuals with depression who visited a primary care
physician and whether race modified the relationship. Patients who reported at least one
chronic condition were found to have a 6% decrease in the probability of using a mental
health service. Race or ethnicity did not contribute to any differences seen in service use.
Considering the relatively high prevalence of depression among cancer patients and the
high rate of depression underdiagnosis and treatment, gaining insight into issues
surrounding screening and cues for identifying depression has public health significance.
Indeed, recognizing the predictors of depression screening in patients diagnosed with
cancer can expedite early and prompt diagnosis with the potential for prompt treatment.
Ultimately, this can improve cancer-related outcomes, including quality of life and
survivability (Koroukian & Sajatovic, 2017).
Problem Statement
Cancer continues to be a leading cause of death in the United States. For example,
over half a million cancer deaths were expected in the United States in 2020 (American
Cancer Society, 2020). Despite new and innovative interventions to curb high cancer
mortality, fatal outcomes are still prevalent. The comorbidity of cancer with chronic
health conditions is common and has been widely studied and shown to contribute to the
increased mortality seen among cancer patients (Park et al., 2017). Depression represents
one of the most frequent mental disorders that occurs comorbidly with cancer (Smith,
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2015). Poorer cancer outcomes, including increased cancer mortality, are associated with
comorbid mental illness (Zhu et al., 2017). With a comorbidity of depression, cancer
mortality drastically increases (Musuuza et al., 2013). In a cohort study of 244,261 adult
patients diagnosed with primary cancer, patients with a first-onset mental disorder,
including mood disorders, were at increased risk of cancer-specific mortality (Zhu et al.,
2017). Therefore, while a cancer diagnosis represents a grave medical condition,
comorbidity with depression presents an additional burden, making it an even more
significant public health issue. Depression is associated with a higher level of stressrelated biomarkers (Strawbridge et al., 2017). Similar chemical imbalances have been
proposed to be a mediating factor in cancer's widespread inflammatory processes
(Koroukian & Sajatovic, 2017). Therefore, adequate treatment of depression comorbidly
occurring with cancer may reduce the inflammatory processes seen in cancer
pathophysiology, potentially impacting the rate of cancer remission, cure, and mortality
outcomes.
Early diagnosis and prompt treatment of depression in cancer are associated with
better cancer outcomes. However, most cases of depression in cancer patients are missed
by medical professionals for several reasons, including inadequate physician training,
increased patient load, and limited time to examine patients’ emotional function
holistically (Popoola & Adewuya, 2012). The adoption of simple screening instruments
has repeatedly demonstrated effectiveness in identifying depressive symptoms among the
cancer patient population. Identifying predictors or determinants of depression screening
can potentially help healthcare providers navigate the process of screening for depression
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among cancer patients (Harrison et al., 2010). However, there is currently no study that
has explored the predictors of depression screening among cancer patients. Therefore,
there is a need for research to examine such potential relationships.
Previous studies have explored national-level predictors of and trends in
depression screening among adult populations with or without a depression diagnosis in
ambulatory care settings (Bhattacharjee et al., 2018; Harrison et al., 2010; Schmitt et al.,
2010). However, no study has examined the predictors of depression screening among
patients who are diagnosed with cancer. Therefore, this study’s objective was to
determine the predictors of depression screening among patients with cancer.
Purpose of Study
The purpose of this research was to determine and evaluate the predictors of
depression screening among cancer patients in ambulatory care settings in the United
States. Therefore, the study explored the factors that predict depression screening for
cancer patients in ambulatory settings. Sociodemographic factors, such as age, gender,
and race, as well as other variables such as physician specialty, time spent with the
physician, and consultation with a mental health provider, were explored as potential
predictor variables in this study. The outcome variable was depression screening
(yes/no). A quantitative approach was used to determine if there were any relationships
between the independent and dependent variables.
Research Questions and Hypotheses
RQ1. Is there an association between consultation with a mental health provider
and screening for depression among patients with a diagnosis of cancer?
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Null hypothesis (H0): There is no statistically significant association
between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
RQ2. Is there an association between time spent with the physician and
screening for depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
RQ3. Is there an association between gender and screening for depression
among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
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RQ4. Is there an association between age and screening for depression among
patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between age and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant
association between age and screening for depression among
patients with a diagnosis of cancer.
RQ5. Is there an association between race and screening for depression among
patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
RQ6. Is there an association between physician specialty and screening for
depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between physician specialty and screening for depression among
patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
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between physician specialty and screening for depression among
patients with a diagnosis of cancer.
Theoretical Framework
Theories powerfully influence how evidence is collected, analyzed, understood,
and used, making it practical and scientific to explore theories and make them
foundational in research development (Alderson, 1998). A useful framework for this
dissertation was the health belief model (HBM). The HBM posits that “messages will
achieve optimal behavior change if they successfully target perceived barriers, benefits,
self-efficacy, and threat” (Jones et al., 2014, p. 566). The key constructs of the HBM
include risk susceptibility, risk severity, benefits to action, barriers to action, selfefficacy, and cues to action (Becker, 1974; Champion & Skinner, 2008).
Knowing the predictors of depression screening among patients with a diagnosis
of cancer can empower patients, practitioners, and stakeholders to begin seeing risks and
thereby potentially stimulate behavioral changes. Such behavioral changes may include
cancer patients seeking mental health consultations even before they are diagnosed with a
mental condition such as depression. Physicians who take care of cancer patients can
learn to recognize cues that prompt them to initiate depression screening discussions.
This idea aligns very well with the concept of value-expectancy, which posits that
behavior can be understood when the value that an individual places on a particular
outcome is known as the likelihood (i.e., expectation) that the action will result in the
desired outcome (Gipson & King, 2012).
This study determined whether there was an association between screening for
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depression, the dependent variable, and the independent variables of age, gender, race,
physician specialty, consultation with a mental health provider, and time spent with
physicians among adults with a cancer diagnosis. A perceived risk severity and risk
susceptibility (of a negative cancer outcome complicated by the co-occurrence of
depression) could motivate patients and their providers to recommend early screening for
depression. Chapter 2 outlines the historical perspective and operationalization of the key
concepts of the HBM.
Based on the HBM, consulting with a mental health provider contributes to risk
perception (perceived susceptibility) for developing depression (Choudhry et al., 2016).
Additionally, spending more time with physicians helps one understand the depth of the
risk (perceived severity) of the various physical, psychological, social, and economic
complications of depression (Bhattacharjee et al., 2018; Wen et al., 2019).
Sociodemographic factors such as gender and age can influence the belief that depression
screening is useful and applicable (perceived benefits) for individuals diagnosed with
cancer (Bhattacharjee et al., 2018; Wen et al., 2019). There is evidence that race may
prevent individuals (perceived barriers) from ultimately taking preventive action,
including undergoing depression screening (Hansotte et al., 2017; Wen et al., 2019). The
physician’s specialty is an external trigger (cues to action) that may increase the
possibility of getting screened for depression (Bhattacharjee et al., 2018; Wen et al.,
2019). Given this study’s objective, which was to determine and evaluate the factors that
can influence screening for depression in ambulatory settings for adults with a cancer
diagnosis, the HBM was an appropriate theoretical framework for this study.
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Nature of the Study
This study was quantitative and used a cross-sectional design. The study's goal
was to determine the predictors of depression screening among cancer patients in
ambulatory settings. Secondary data from the National Ambulatory Medical Care Survey
(NAMCS), which comprises a national probability sample of visits to the emergency and
outpatient departments of noninstitutional general and short-stay hospitals, were
analyzed. The NAMCS data were designed to meet the need for objective, reliable
information about the provision and use of ambulatory medical care services in the
United States. The database is open to the public and easily accessed by going to a
website. The data were collected using surveys that captured physician-patient encounters
or clinic visits. These encounters could have involved direct or personal interactions
between patients and their physicians or clinic staff working under the direct supervision
of a physician. A multistage probability sampling design was employed to collect the
NAMCS data (National Center for Health Statistics [NCHS], 2015). This involved
probability samples of primary sampling units (PSUs), physician practices within PSUs,
and patient visits within practices. The second stage involved a probability sample of
practicing physicians, and the final stage was the selection of patient visits within the
annual practices of sample physicians.
The logistic regression model was used to analyze the data and test whether the
independent variables predicted the dependent variable. Logistic regression is ideal for
testing models when there is one nominal and two or more measurement variables
(Pallant, 2010). As a statistical model, the logistic regression describes the relationship
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between an independent variable and a binary dependent variable. The independent
variables could be one or more nominal, ordinal, or interval level independent variables
(Nick & Campbell, 2007). Therefore, the one dependent variable that I used in the study
was dichotomized, and the use of logistic regression was justified.
Definitions
A concise definition for each of the independent and dependent variables as used
in this study is provided below:
Depression: A mood disorder characterized by an experience of persistent
feelings of sadness, hopelessness, and loss of interest. Depression, as used in the study,
includes both symptoms of depression and any of the five classifications of a depressive
disorder by the American Psychiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, 2013).
Screening: “Screening for diseases is the examination of asymptomatic people to
classify them as likely or unlikely to have the disease that is the object of screening.
People who appear likely to have a disease are investigated further to arrive at a final
diagnosis. Those people who are found to have the disease are then treated” (Morrison,
1992, p. 3).
Depression screening: The use of validated and nonvalidated instruments to
identify asymptomatic people to classify them as likely or unlikely to have depression.
Mental health provider: This refers to psychologists, counselors, social workers,
and therapists who provide mental health counseling, including psychiatrists.
Cancer: A disease whereby a single normal body cell undergoes a genetic or
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metabolic transformation characterized by an uncontrolled division of abnormal cells in a
part of the body. The term is used with any body site.
Time spent with a physician: The amount of time (in minutes) that a physician
spends with a patient, not including time that the patient spends waiting for an
appointment or with another type of practitioner (NCHS, 2007).
Assumptions
In this study, I attempted to identify the predictor variables for depression
screening among cancer patients using secondary data collected by the NAMCS. The
data consisted of surveys administered to patient populations in the ambulatory care
setting across the United States. One of the assumptions for this study was that the
respondents answered the survey questions as truthfully as possible. The NAMCS used
surveys to obtain data about physicians’ services rendered to ambulatory patients during
office visits. The questions asked were not sensitive, and therefore there were no
expectations that the responses were laced with falsehood. Information collected from the
surveys included service delivery, prescribed medication, patient characteristics,
physician characteristics, and diagnoses.
Scope and Delimitations
The study may influence the approach taken in screening cancer patients for a
comorbid diagnosis of depression. Comorbid depression can lead to a poorer cancer
outcome, especially when the depression is not identified and treated (Zhu et al., 2017).
Prompt identification and subsequent treatment lead to an improved patient experience
(PDQ Supportive and Palliative Care Editorial Board, 2019). The study’s scope included
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physician-patient encounters or visits focusing on patients with a cancer diagnosis
irrespective of the cancer site who were screened for depression in the ambulatory care
setting in the United States. The sampling design used to collect data was multistage
probability sampling, which involved taking samples in stages using smaller and smaller
sampling at each stage.
The study was limited to physician-patient interactions occurring in the
ambulatory care setting. As such, only variables related to physician-patient interactions
were explored as independent variables. The results from this study create a foundation
for exploring other predictors of depression screening among cancer patients.
Limitations
The potential limitations of this study should be noted. First, the data used in the
analysis were cross-sectional, which did not allow for inferences regarding causation.
Additionally, a potential limitation that may be related to using existing data from a large
national database is study-specific nuances or glitches occurring during the data
collection process, which may be important to the interpretation of some specific
variables but may not be immediately obvious (Cheng & Phillips, 2014). Other
limitations included those related to the collected variables, including lack of information
on specific cancer types/sites.
Significance
Research is increasingly being evaluated by its significance and essential
contributions to society and not just on its scientific impact (Bornmann, 2012). A
dissertation topic focusing on establishing the factors associated with screening for
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depression among patients with a cancer diagnosis can have a long-lasting positive effect
on the population. As noted in the preceding section, cancer complicated by depression
has important outcomes related to poor quality of life, increased cost of treatment, and
higher morbidity and mortality. Therefore, this study determined the factors that predict
which cancer patients will get a depression screening in the ambulatory setting. The study
may contribute to society by stimulating new approaches to managing patients with
comorbid conditions and informing public debates and policy-making strategies
necessary to promote social change.
Summary
Depression occurring comorbidly with cancer continues to represent a significant
public health problem. The burden on affected patients and their caregivers cannot be
overemphasized. Improved depression diagnostic efforts followed by prompt treatment
will go a long way toward alleviating the excess burden arising from the comorbidity.
Gaining a deep understanding of how patients get screened for depression and the
predictors for such screening should be one of the first steps in improving outcomes in
patients with comorbid cancer and depression.
In this chapter, I presented an introduction and background for the study's topic,
including a summary of the literature. I emphasized the study’s public health significance
and the problem associated with cancer and depression comorbidity and lack of adequate
screening for depression among the patient population. I summarized the methodology
that I used, including the study population and collection of secondary data. Additionally,
I highlighted how the theoretical framework relates to each of the variables used in
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defining the research questions. Finally, I discussed the study scope, delimitations,
limitations, and anticipated assumptions.
Chapter 2 will contain an extensive review of the literature covering the
prevalence of depression and cancer, the interaction between depression and cancer,
predictors of depression in cancer patients, determinants of depression screening among
cancer patients, and access to depression screening. Importantly, the literature search
strategy will be outlined. A historical account of the theoretical framework used will be
discussed. Additionally, I will describe how the theory relates to the study, and how it
will be appropriately integrated for application and use in the study. In Chapter 3, I will
discuss the research methodology, which will be followed by the presentation of the
study results in Chapter 4. I will conclude with Chapter 5, which will include a
discussion, recommendations, a summary, and a conclusion.

17
Chapter 2: Literature Review
Introduction
Depression occurs commonly among cancer patients, with some studies showing
a pooled mean prevalence ranging from 8-24% (Krebber et al., 2014). Despite the high
prevalence of depression among cancer patients, it is often unrecognized and untreated,
thereby representing an enormous psychological distress source among the cancer patient
population (Abid et al., 2018). Comorbid depression is associated with poorer cancer
outcomes (Alemayehu et al., 2018; Smith, 2015). For example, the presence of comorbid
depression significantly worsens the quality of life of cancer patients (Larkin, 2020).
Compared with nondepressed cancer patients, depressed patients are more likely to have
cancer that progresses and is invasive (Lin et al., 2018; Smith, 2015). Poor compliance
with medical therapy and poor cancer survivability have also been identified as common
outcomes of the co-occurrence of depression and cancer (Pasquini, & Biondi, 2007).
While routine screening for depression has been recommended and endorsed both
locally and internationally as an effective measure, the uptake of routine screening for
depression among patients with cancer and other chronic disease conditions is not
optimal (PDQ Supportive and Palliative Care Editorial Board, 2019). Existing published
research has addressed the predictors, patterns, and trends of depression screening among
adult populations with and without depression in the ambulatory care setting
(Bhattacharjee et al., 2018; Harrison et al., 2010). However, there are currently no
published studies investigating depression screening among cancer patients, including
potential determinants and predictors of screening among this population in the
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ambulatory care environment.
The ambulatory care setting represents one of the most frequent contact points
where patients with comorbidities meet with healthcare professionals (Carrera-Lasfuentes
et al., 2015). Combined data analysis of the 2001 and 2002 NAMCS and National
Hospital Ambulatory Medical Care Surveys (NHAMCS) found an average estimate of
1.1 billion visits per year to physician offices, hospital outpatient departments, and
emergency departments. This is an equivalent of 3.8 visits per person annually (Schappert
& Burt, 2006). Despite the large volume of patient flow in ambulatory care settings, there
is evidence of relatively good care coordination for patients visiting different specialists
(Valderas et al., 2009). Comorbidity is related to the rate of utilization of ambulatory
medical care (van den Bussche et al., 2011). This study determined the predictors of
depression screening among cancer patients attending ambulatory care settings in the
United States.
The chapter will extensively review the literature relevant to screening for
depression among patients diagnosed with cancer and the various predictors of
depression screening in the patient population. The chapter will start with an outline of
the HBM, the theoretical framework for this study. Specifically, I will review the
prevalence of depression and cancer, the interaction between depression and cancer,
predictors of depression in cancer patients, potential determinants of depression screening
among cancer patients and/or patients with other chronic diseases, barriers, access to
depression screening, screening, the prevalence of depression screening, and depression
screening recommendations and patient outcomes.
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Literature Search Strategy
The databases searched included Medline/PubMed, Ovid, Embase, CINAHL, and
PsycINFO. I also explored the Walden University Library and Google/Google Scholar
search engines. In searching these electronic databases, I used specific search terms,
including depression screening (screening and depression) AND cancer patients. The
same combination of search terms was entered into all the databases. Reference lists of
included articles were equally examined to identify further journal articles that might
have been missed. Limits were placed in some of the databases to concentrate on relevant
articles. Such limits included the English language, human, and articles published within
the past 5 years. The article abstracts were exported to an Excel spreadsheet, and the
articles were subsequently scanned to enable the removal of articles that appeared
obviously out of scope. Articles that were the most pertinent were reviewed. While the
searches were generally limited to 5 years (2015–2020), some research articles used to
review the theoretical framework were older than 5 years. Some of these articles
consisted of seminal articles to give the necessary historical account of the chosen theory
as well as to establish the contextual facts and how the theory had evolved over the years.
Theoretical Framework
The HBM is one of the most extensively used health behavior theories (Glanz &
Bishop, 2010). The model was originally formulated in the United States in the 1950s by
social scientists working to explore the reason why people refuse to adopt preventive
health behavior, including screening that can detect disease in the early phase
(Rosenstock, 1974). The central tenet of the HBM was significantly influenced by the
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theories of Kurt Lewin. The early social psychologists working on the theory of the HBM
built most of their work on his theory.
The HBM was originally conceptualized to include constructs relating to
perceived susceptibility, perceived severity, as well as perceived benefits and perceived
barriers (Rosenstock, 1974). Perceived susceptibility and perceived severity are
indicative of a disease state, while perceived benefits and perceived barriers refer to the
behavioral action that must be adopted by the individual to avoid or reduce the risk of a
disease condition.
Rosenstock (1974) described three different ways that individuals may internalize
the construct of perceived susceptibility. Some individuals may not believe that they are
susceptible to a disease. Other individuals may recognize the scientific possibility of a
disease occurring but believe that they are unlikely to be affected by it. Finally, some
individuals may acknowledge the presence of the real possibility of becoming affected by
the disease.
Perceived severity refers to the degree to which individuals believe that they can
be negatively affected by a disease (Orji et al., 2012). Perceived benefits refer to adopting
a health behavior based on the perceived advantages that an individual believes that the
new behavior could lead to, in terms of subjective reduction of susceptibility to or
severity of disease (Jones et al., 2015). Perceived barriers indicate the various negative
actions or attributes associated with making a health behavior change (Jones et al., 2015).
Perceived barriers could be unpleasantness and inconvenience associated with the steps
necessary for the behavioral change, or barriers related to the financial cost of the desired
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behavior change. All of these components work in concert to influence whether an
individual acts or not.
Approximately 20 years after the initial construct of the HBM was introduced, as
more prospective studies were designed, the construct of self-efficacy was added to the
HBM (Boslaugh, 2013). Self-efficacy is a concept that was originally developed by
Albert Bandura, a social psychologist (Bandura, 1977). The concept refers to the
confidence that people have about their ability to perform a behavior. An additional
variable called cues to action was introduced, which was considered to be necessary to
complete the model at the time. As individuals begin to consider making appropriate
behavioral changes, the combination of susceptibility and severity in concert with the
perception of benefits or fewer barriers may not be enough to stimulate the action
required. A trigger, or a cue, appears to be necessary to complete the behavioral change
cycle. Based on Rosenstock’s original description, cues to action could be internal cues
by which an individual could perceive a change in bodily state or external cues such as
interpersonal interactions. Cues to action could represent any factors that can instigate
health behavior change or prompt an individual to take a health-related action. Over time,
other modifying variables, such as social, psychological, and demographic factors that
play important roles in individuals’ decisions to take action, were added to the HBM.
Jones et al. (2015) described three basic models related to variable ordering that
could be relevant to the operationalization of the HBM. In the first model (parallel
mediation), the independent variables (e.g., gender and age) influence the HBM
constructs, which in turn influence the dependent variable (e.g., screening for
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depression). The model conceptualizes the HBM constructs as channels of influence,
where the independent variables are seen as influencing outcome variables through one or
more of the channels. The authors also described a second model in which each construct
of the HBM connects in a causal chain. In the third model (moderated mediation model),
individual constructs that form the HBM may serve as moderators for the other constructs
to exert their influence toward stimulating a behavior change. For example, in order for a
potentially predicted behavior to occur in the light of perceived benefits and perceived
barriers, the perception of threat needs to be greater. In this example, the perception of
threat moderates the effect or influence of both perceived benefits and perceived barriers
on the specific behavior change (Champion & Skinner, 2008).
The present study determined whether there is an association between screening
for depression, the dependent variable, and the independent variables of age, gender,
race, physician specialty, consultation with a mental health provider, and time spent with
physicians among adults with a cancer diagnosis. Based on the HBM, a cancer patient
who consults with a mental health provider contributes to risk perception (perceived
susceptibility) for developing depression (Choudhry et al., 2016). Additionally, spending
more time with physicians helps one to understand the depth of the risk (perceived
severity) of the various physical, psychological, social, and economic complications of
depression (Bhattacharjee et al., 2018; Wen et al., 2019). The tendency to discuss other
related health issues outside of the primary cancer diagnosis is likely to occur as a
function of how much time a patient and doctor spend together in consultation.
Sociodemographic factors such as gender and age can influence the belief that depression
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screening is useful and applicable (perceived benefits) for individuals diagnosed with
cancer (Bhattacharjee et al., 2018; Wen et al., 2019). There is evidence that race may
prevent individuals (perceived barriers) from ultimately taking preventive action,
including undergoing depression screening (Hansotte et al., 2017; Wen et al., 2019). The
specialty of the physician is an external trigger (cues to action) that activates discussion
between patients and their physicians, and the possibility of getting screened for
depression (Bhattacharjee et al., 2018; Wen et al., 2019).
Specialists, including oncologists, pediatricians, and psychiatrists, are the health
care providers with the most frequent contact with patients with potential comorbid
depression and cancer in the ambulatory care setting and can potentially play vital roles
in the detection of depression among the cancer patient population (Agapidaki et al.,
2013). Despite the pivotal position that these health care professionals occupy, the
underrecognition and undertreatment of depression cannot be overemphasized. The
literature has identified some specific health-care-provider-related barriers to screening
for depression. These include attitudinal predisposition (Heneghan et al., 2007),
inadequate dedicated time resources, increased workload, and poor communication
between cross-functional team members (Horwitz et al., 2007). Few authors have used
the HBM to explore the interaction of factors among health care providers that may
predict or serve as barriers for depression screening among their patients. Agapidaki et al.
(2013) examined the impact of an HBM-based educational intervention on pediatricians
for the purpose of improving early identification and management of depression among
mothers. The authors assessed the pediatricians’ knowledge, self-efficacy, and attitudes
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concerning maternal depression at baseline and postintervention. They reported that
pediatricians in the intervention group demonstrated increased perceived responsibility
and increased self-efficacy for detection and referral of maternal depression.
While there is a dearth of literature on the application of HBM constructs to
determinants of depression screening among cancer patients, several authors have
explored the role of HBM as a theoretical framework to study the predictors of screening
for various health conditions. For example, VanDyke et al. (2017) applied the HBM as a
determinant of breast cancer screening among 170 women aged 18-78 years in rural
Appalachia. The frequency of mammography among respondents was found to be a
function of an objective heightened risk and poorer prognosis of breast cancer, which is
consistent with HBM expectations. Participants with poor prognosis also perceived
greater benefits and fewer barriers to mammography screening. The authors, however,
noted that mammogram frequency was not predicted by perceived susceptibility, severity,
as well as benefits of mammography, a finding that did not completely fit into the HBM.
Similarly, other authors demonstrated that women with lower perceived barriers to
screening were more likely to undergo mammography compared to those with higher
perceived barriers (Lee et al., 2015). In a prospective study that aimed to identify the
predictors of intention to get screened and subsequent attendance at flexible
sigmoidoscopy screening using constructs derived from the HBM, a higher score on a
scale of benefits was positively associated with intention for screening, while intention
was negatively associated with a higher score on perceived barriers. Attendance,
however, was predicted by perceived benefits as well as perceived barriers (von Wagner
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et al., 2019).
Elias et al. (2017) explored the patterns and determinants of mammography
screening among 2,400 Lebanese women ≥ 40 years of age. The association between
having ever used and/or repeated mammography and psychosocial and sociodemographic
factors was tested. Being older and of higher socioeconomic status (SES) were
significantly associated with everuse of mammography. Compared to respondents that
were designated “nonrepeaters,” “repeaters” were also significantly older. Specific to
repetition of mammography, the psychosocial HBM variables that aligned best with the
outcome of repeating mammography included higher perceived susceptibility to the
disease, ease of access, and higher perceived comfort of the previous mammography
encounter.
Literature Review
Prevalence of Depression and Cancer
Depression represents the most common mental health disorder in the general
population (Sinyor et al., 2016). According to a recent World Health Organization
(WHO) report, approximately 4.4% of the world’s population, representing over 300
million people at a global level, are estimated to suffer from depression (WHO, 2017).
This represents an increase of 18.4% between 2005 and 2015 (GBD, 2015). The
prevalence of depression in the population is difficult to estimate, partly because different
researchers use different diagnostic criteria to measure depression. Some structured
interview schedules that investigators have used to make an accurate and valid diagnosis
and that have helped with prevalence measurement include the Diagnostic Interview
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Schedule (DIS), the Schedule for Clinical Assessment in Neuropsychiatry (SCAN), and
the Composite International Diagnostic Interview (CIDI; Brugha et al., 2001). A recent
meta-analysis reported the aggregate point, 1-year, and lifetime prevalence of depression
as 12.9%, 7.2%, and 10.8%, respectively (Lim et al., 2018). There is evidence that rates
of depression are approximately twice as high in females compared to males (Baxter et
al., 2014; Whiteford et al., 2013). The gender difference was present as early as age 12,
peaked during the adolescent years, and first declined but then remained stable in later
years (Salk et al., 2017). Depression is the leading cause of disability worldwide and one
of the significant contributors to the global burden of disease (Friedrich, 2017). In the
United States, depression is a significant cause of decreased workplace productivity, and
up to $36.6 billion is lost every year as a result of poor workplace productivity caused by
depression (Lépine & Briley, 2011).
Cancer is a chronic disease that constitutes a major public health challenge around
the world. In the United States, approximately 40% of men and women will have a
diagnosis of cancer at some point in their lifetime (Arem & Loftfield, 2017). The
commonest cancers among men include prostate, lung, colon, urinary bladder, and
melanoma of the skin, while among females, the commonest cancers include breast, lung,
colon, corpus and uterus, and thyroid (Cronin et al., 2018). From 2010 to 2014, the
incidence rates of the seven commonest cancers among men and women were reduced
(Cronin et al., 2018). Although there was a 29% decline in overall cancer deaths between
1991 and 2017, cancer continues to be one of the leading causes of mortality in the
United States (Siegel et al., 2020). In 2020, 606,520 cancer deaths were projected in the
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United States (Siegel et al., 2020). Based on data collected from 2001 through 2016/2017
from the Centers for Disease Control and Prevention (CDC), National Cancer Institute
(NCI)-funded population-based cancer registries, and the NCHS National Vital Statistics
System, cancer death rates decreased on average by 1.5% per year from 2013 to 2017,
1.8% per year among males and 1.4% per year among females (Henley et al., 2020). The
burden of cancer continues to increase in the United States and worldwide (Arem et al.,
2017). Spending associated with cancer care is high and continues to grow, putting a
huge strain on not only the nation, states, and health insurance plans, but also individual
family budgets (Yabroff et al., 2019).
There is an abundance of evidence from epidemiological studies that depression
commonly occurs comorbidly with cancer (Nikbakhsh et al., 2014). Depression is a
chronic disabling disorder that occurs in about 10-25% of cancer patients (PDQ
Supportive and Palliative Care Editorial Board, 2019). Studies have demonstrated a 25%
mortality rate for cancer patients with comorbid depressive symptoms, and a 39%
mortality rate among cancer patients with full-blown major depressive disorders (Mustafa
et al., 2013). The gender difference in depression incidence rate among the general
population is reversed among cancer patients, as men with cancer report more depression
symptoms than women with cancer (Pudrovska, 2010). This is in contrast to the general
population, where the incidence of depression in women is almost twice the incidence in
men (Baxter et al., 2014). There is evidence that cancer has more adverse psychological
effects on men compared to women. Also, male cancer patients reported 1.4 more days
per week of symptoms of depression compared to their matched controls without cancer
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(Pudrovska, 2010). Cancer affecting the genitourinary system appears to have especially
more adverse depressive symptoms among men.
Interaction Between Depression and Cancer
Comorbidity can be described as the co-occurrence of two disorders. As a
generalization, a mental illness such as depression can occur with a medical condition
such as cancer for three main reasons (Michael, 2007):
1. The two conditions may occur together as a coincidence.
2. The mental disorder or symptoms may have given rise to the medical
condition; for example, anorexia nervosa may give rise to serious endocrine
consequences that may lead to amenorrhea or severe bone loss.
3. The medical condition, on the other hand, may have given rise to the mental
disorder through either the effect of the medical condition and/or its treatment,
adverse psychological response to the medical condition and/or its treatment,
and/or adverse social response to the medical condition or its treatment.
Depression is a mental illness that often occurs comorbidly with medical
conditions such as cancer. In cancer patients, the etiology of depression could be
multifactorial, and like the association between other mental illnesses and medical
conditions, it could occur coincidentally. However, the association could also be
psychosocial or biological (Smith, 2015).
Some patients have depressive symptoms or a diagnosis of depression that predate
their cancer diagnosis, while other patients develop depression after being diagnosed with
cancer (Michael, 2007). Depression occurs as a result of chemical imbalances in the
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brain. It also involves a complex pathology that transcends the neurobiological
mechanism to include environmental stressors and genetic vulnerability.
Often, the development of depression among cancer patients could be a
psychological reaction to a cancer diagnosis. The symptoms of depression sometimes
overlap with psychological reactions to the unpleasant news of a cancer diagnosis as well
as some symptoms of cancer, such as poor sleep, pain, and tiredness (Michael, 2007). A
cancer diagnosis represents a life-changing experience that a patient needs to negotiate
and adapt to. A defective coping style may lead to poor adjustment, which may culminate
in depressive symptoms or full-blown major depressive disorders (Chou et al., 2011).
Indeed, psychological distress such as depression is well documented among patients
diagnosed with life-threatening illnesses such as cancer (Jacobsen & Jim, 2008). The
negotiation and the acceptance of a new diagnosis of cancer can be likened to the five
stages of dying that were first described by Elisabeth Kubler-Ross, a Swiss psychologist
in 1969 (Kübler-Ross, 1969). The stages are a psychological reaction to a severe life
event. In the first stage, the patient is typically in denial, and it is not uncommon for
him/her to believe there has been a mistake in the diagnosis or the prognosis. This may
lead to the second stage, comprised of anger and frustration, especially when the
individual realizes that denial cannot continue. The anger stage gives way to the third
stage, i.e., bargaining. At the bargaining stage, the patient tries to negotiate to avoid a
negative outcome. Commonly, patients may make remarks such as promising never to
smoke again if their cancer can be cured (Tyrrell et., 2020). Depression is the fourth
stage, and patients express despair and hopelessness. Patients then move on to the last
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stage, which is acceptance. People respond to stress in different ways, including the use
of coping strategies. The purpose of a coping strategy is to attenuate the effect of stressful
events. Still, when the stress saturates the coping strategy or coping style of an individual,
the ability to adjust may be impacted, leading to depressive symptoms.
The social effect of having cancer and cancer treatment may facilitate the
development of depression. For example, the loss of a job as a result of cancer may act
synergistically with the patient’s underlying premorbid vulnerabilities, which can
precipitate a depressive episode. Evidence of the interaction between social impact and
depression in cancer patients was demonstrated by authors who showed that emotional
support from family members and friends acts as a protective factor against the
development of depression (Linden et al., 2012). Social support impacts both cancer and
depression outcomes in patients with comorbid cancer and depression. Some authors
have shown that cancer survivability improved significantly among patients with
adequate social support, and in addition to the survival benefits , the level of depression
and other mental disorders were significantly reduced (Kroenke et al., 2006; Hopko et al.,
2015). Additionally, cancer treatment can act as a stressor which in vulnerable patients,
and within the right environmental milieu, could lead to depression (Michael, 2007). In
terms of biological interaction, some authors have identified uncontrolled pain, metabolic
and endocrine abnormalities, as well as concomitant medications as potential medical
causes of depressive symptoms in people with cancer (PDQ Supportive and Palliative
Care Editorial Board, 2019).
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Predictors of Depression in Cancer Patients
Over the past decades, there have been significant advances in cancer treatment.
As a result, the number of patients surviving a diagnosis of cancer continues to grow. In
the approximately 1.6 million people diagnosed with cancer every year, the relative 5year survival rate across all cancer types approaches 70-78% (Allemani et al., 2018). As
more patients continue to transition into cancer survivorship, it is critical to understand
both the short-term and long-term psychosocial adjustment that is part of the disease
process. Depression is particularly common among this patient population; hence it is
crucial to study the markers, predictors, and trends in depression screening among cancer
patients.
Several potential predictors of psychological distress and depression among
cancer patients have been identified, including the need to relocate for treatment and
being a former smoker (Clinton-McHarg et al., 2014), tumor stage (Tsuguo et al., 2013),
psychosocial factors (Godding et al., 1995; Hamilton et al., 2013), and quality of life
(Godding et al., 1995). A few researchers have explored the different factors that
influence how cancer patients adjust to their cancer diagnosis and how these are
associated with the development of psychological symptoms such as depression.
Schapmire and Faul (2017) investigated predictors of depressive symptoms over a period
of eight years among respondents ages 50 – 91 years. They found that a diagnosis of
cancer in patients without aspouse/partner in the home, and cancer diagnosis and lower
life expectancy were associated with a higher probability of having a concurrent
depression. The authors also identified a significant three-way interaction between
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cancer, gender, and social support, in which female cancer patients with poor social
support were found to be at a higher risk of developing depression. Other studies did not
find a significant relationship between social support and depression among cancer
patients. Yoon et al. (2018) examined the relationship between social, cultural, and
appraisal factors and depression and quality of life among Korean American population.
While the authors demonstrated a statistically significant relationship between higher
levels of social support and higher quality of life, they failed to establish a statistically
significant relationship between social support and depression. However, they still found
that more negative appraisal of illness tended to predict the development of depression
among cancer patients (Yoon et al., 2018). However, other authors that have studied a
similar population of Korean Americans reported that social support was significantly
related to depression in cancer patients (Hae-Ra et al., 2008). The two studies used
different social support measures, and the sample characteristics were also different,
which may have explained the differences in the two studies. More evidence of social
support as a predictor of depression among cancer patients has been reported in other
recent literature. Specifically, the absence of a partner was identified as a risk factor for
developing depression among patients with gynecological malignancies (Klügel et al.,
2017).
Other authors have suggested that the degree of social support a cancer patient
receives may not be as important as the ability of cancer patients to receive compassion
from others as a predictor of depression symptomatology. For example, Trindade et al.
(2018) explored the predictors of depressive symptoms in a sample of patients diagnosed
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with breast cancer. Social support and fear of receiving compassion from others were two
predictors examined. The authors found that the fear of receiving compassion from others
was a significant predictor but not social support.
There is increasing evidence of the relationship between depression and sexual
function among cancer patients. For example, in a study of 83 women that were
successfully treated for their stage 1b cervical cancer, psychological distress scores were
significantly correlated with sexual outcomes, functional outcomes and physical
complaints (Cull et al., 1993). The authors reported that the 61 women who admitted to
optimal sexual experience prior to treatment all reported a sexual function that was
significantly poorer compared to pre-morbid sexual function. Similar trends have been
consistently reported in the literature among similar populations (Lau et al., 2013). More
recently Klügel et al (2017), conducted a critical review of the literature and identified
sexual inactivity as one of the factors that predicts depression among patients diagnosed
with cancer.
Age has been shown to be one of the sociodemographic factors that is
significantly associated with depression among cancer patients. Wondimagegnehu et al
(2019) demonstrated an inverse association between depression andage. Specifically, the
authors showed that the risk of having depression decreased by as much as 60-80% as
age increased. Patients that were greater than 30 years of age tended to have a lower risk
of depression than those 19-20 years of age. Similarly, a study that examined the
demographic factors associated with continuous distress in the year following cancer
diagnosis reported younger age as a predictor of occasional or continuous distress,
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including depressive symptoms in cancer patients (Enns et al., 2013). Vodermaier et al.
(2011) also reported that fewer depressive symptoms were observed in older cancer
patients.
Determinants of Depression Screening Among Cancer Patients
The purpose of screening for depression among cancer patients seeking treatment
is to promptly identify patients with otherwise unrecognized symptoms of depression
seeking cancer treatment for subsequent referral to confirm a minor or major depressive
disorder and for subsequent treatment (Meijer, et al., 2011). There is a dearth of
information on the potential predictors of screening for depression in cancer patients. In
addition, few studies have investigated predictors of depression screening among noncancer study populations. Two studies used pooled data from the National Ambulatory
Medial Care Survey (NAMCS), a nationally representative sample. In one of these
studies, Bhattacharjee, et al. (2018) examined the predictors of and trends in depression
screening among adults without a diagnosis of depression who made an ambulatory care
visit to a non-psychiatrist. The authors found that the amount of time spent with the
physician, geographical region and metropolitan location, physician specialty, as well as
gender of the patient were significantly associated with receipt of depression screening.
Barriers and Access to Depression Screening
The importance of prompt access to screening for mental health and the ability to
identify patients in need of both initial and follow-up care cannot be overemphasized.
However, there have been extensive studies demonstrating significant disparities in the
recognition and treatment of depression. Some of these studies have established that
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racial-ethnic inequalities constitute a major problem, with people of minority groups
having the least probability of screening for depression (Roberto et al.,2005). A study that
evaluated disparities in depression screening and care by gender and race of patients
found wide variability by gender, implying the need to consider interactions among
patient variables as opposed to exploring screening and mental health utilization based on
consideration of a single segment of the population (Hahm et al., 2015).
Barriers to screening for depression are multifactorial and could be classified into
those factors relating to the patients and those relating to health care providers. Patientrelated factors include the inability to find childcare, problems accessing transportation,
and other challenges specific to role responsibilities of women. These factors represent
specific barriers to accessing depression care, such as depression screening (Hahm et al.,
2015). Patients generally perceive that their providers are prone to neglect their
psychosocial needs compared to their physical needs (Adler & Page, 2008). This
disparity may be due to a lack of providers of the same racial-ethnic background whom
they can trust and not feel stigmatized. Differences in language, barriers related to health
literacy, predominant somatic presentation, and use of cultural idioms of distress during
presentation to health care providers make under-recognition of depression a notable
problem, particularly among minority ethnic groups (Roberto et al., 2005). Making a
diagnosis of depression requires skills and a thorough assessment of patients. Greenberg
(2004) reported that there is enormous lack of confidence and self-efficacy among
clinicians that are not psychiatrist in confidently making a diagnosis of depression among
cancer patients, which is usually compounded by the time demand on the health care
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provider. Indeed, lack of time has been shown to be the main barrier to the successful
screening for distress and other mood-related symptoms, such as depression, among
cancer patients (Mitchell et al., 2008). The study also found other factors related to the
health care provider, such as sub-optimal training and low confidence, which constitute
essential barriers to screening.
Healthcare providers may tend to focus more on physical symptoms co-occurring
with cancer than depression and other psychological symptoms. Alison et al. (2016)
explored whether there was any difference between screening for physical versus
emotional symptoms by the providers of cancer patients. While they found no significant
variation, they reported a lower tendency to screen for emotional symptoms, including
depression, compared to pain and other types of physical symptoms.
Screening
The conference on Preventive Aspects of Chronic Disease held by the
Commission on Chronic Illness in 1951 defined screening as “the presumptive
identification of unrecognized disease or defect by the application of tests, examinations,
or other procedures which can be applied rapidly. Screening tests sort out apparently well
persons who probably have a disease from those who probably do not. A screening test is
not intended to be diagnostic. Persons with positive or suspicious findings must be
referred to their physicians for diagnosis and necessary treatment” (Commission on
Chronic Illness, 1957 Chapter 5, p. 45). The World Health Organization report (WHO) in
1966 further elaborated on the definition of screening and the principle of early detection
of disease and scientific aspects of screening procedures. From the initial definition, the
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WHO noted that “other procedures” could also potentially embrace the use of
questionnaires in screening (World Health Organization, Wilson, & Jungner, 1966). The
U.K. National Screening Committee in 2000 further defined screening as “a public health
service in which members of a defined population, who do not necessarily perceive they
are at risk of or are already affected by, disease or its complications, are asked a question
or offered a test to identify those individuals who are more likely to be helped than
harmed by further tests or treatment to reduce the risk of disease or its complications”
(page 6). The definition of and emphasis on the science of screening have evolved over
the years with more focus assigned to the potential side effects arising from the screening
procedures and potentially no benefit to the patient being screened. Emphasis has been
placed on the need for more rigorous standards of evidence to improve the effectiveness
of all screening. Reduction in morbidity and mortality due to the early detection of
disease drives the objective of screening tests, especially when a treatment exists for the
condition being tested for (Maxim et al., 2014). As part of the appraisal, viability,
effectiveness, and appropriateness of a screening program, the National Screening
Committee (U.K.) proposed a set of criteria that must be met before screening for a
condition is initiated (Kitchener, et al., 2014). These include an emphasis on the
condition being screened for (which should be an important health problem), the test
(which should be simple, safe, precise, and a validated screening test), the treatment
(implying that there should be an effective treatment for all patients identified through
early detection with better outcomes compared to late treatment) and finally, the
screening program (which should demonstrate effectiveness in reducing mortality or
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morbidity).
Prevalence of Depression Screening
Despite the numerous local and international guidelines that have recommended
routine screening for depression among medical patients, including cancer patients,
depression remains highly unrecognized (Ng, How, & Ng, 2016). While there are not
many studies on the prevalence of depression screening among cancer patients, there are
few studies that have reported on the prevalence rates of depression screening among the
adult population in general (Desai et al., 2006; Farr et al., 2011; Tudiver et al., 2010).
Desai et al. (2006) conducted a chart review of the Department of Veterans Affairs (VA)
medical outpatients with no history of depression or any mental health visit within the
past six months. The authors found that while younger and unmarried patients and
patients with more medical comorbidity were more likely to be positive when screened,
they were generally less likely to be screened.However, VA facilities that tended to spend
more on mental health care were more likely to screen for depression. A similar study
that also conducted a chart review of women’s records in 19 rural health clinics reported
that patients with a history of anxiety as well as younger women had higher probabilities
of being screened (Tudiver et al., 2010). In terms of patients’ gender, some studies
reported no difference in depression screening rates between women and men among
patients of all ages (Desai et al., 2006). Harrison, et al. (2010) estimated the probability of
screening for depression among U.S. adults using a nationally representative sample and
reported a 2.29% prevalence of depression screeningduring community-based physician
practice visits. Other authors reported a lower nationallevel depression screening
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prevalence rate of 1.4% (Bhattacharjee et al., 2018). The two studies occurred at a time
during which the USPSTF recommendation for depression screening among adults was
dependent on the presence of programs that could assure follow up treatment of those that
screened positive (Siu et al., 2009). The recommendation was subsequently revised to
accommodate screening for all adults irrespective of available capacity to follow up with
treatment (Siu et al., 2016). The low prevalence reported by these authors could have
been a factor of the older recommendation by USPSTF (Bhattacharjee et al., 2018).
There is evidence that residents and physicians working in specialties other than
psychiatry are not adequately prepared to recognize depression. Dietrich and colleagues
(2003) conducted a survey among obstetrics/gynecology residents in their final year or
recent graduates concerning their attitude related to depression care. They found that less
than 50% of the respondents acknowledged that they were well prepared to identify
depression in their patients. Not more than 12% of the respondents routinely inquired
about depressive symptoms, and the recognition of symptoms was predominately based
on patients’ distressed appearance as well the patient talking about depression directly.
The role of primary care physicians in depression screening has also been studied.
Glasser et al. (2016) conducted a cross-sectional study of primary care physicians
regarding their attitudes and practices in managing depression in the post-partum period.
Family medicine physicians were found to be more willing than pediatricians to screen
for depression. However, there was no difference between physicians by gender when
comparing all respondents.
Depression Screening Recommendation and Patient Outcome in Cancer
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Cancer continues to be the leading cause of death in the U.S. with more than
1,806,590 estimated new cases and 606,520 deaths expected in 2020 (Siegel et al., 2020).
Considering the advancement in cancer diagnostics and treatment options, the overall
outcome of cancer cases can still be described as poor, and cancer is still one of the most
dreaded diseases. Comorbidity with depression contributes an additional burden to
patients that are affected. For example, the quality of life of patients with comorbid
cancer and depression is significantly lower compared to cancer patients without
depression (Wondimagegnehu, et al., 2019). This reduced quality of life has been
partially attributed to the frequent lack of recognition of depression in cancer patients. As
a generalization, there are indications that there is a high prevalence of undiagnosed
depression in the general and cancer populations (Popoola & Adewuya, 2012; LloydWilliams, 2003). Williams, et al. (2017) explored the prevalence of undiagnosed
depression in a lower-income neighborhood in northern Manhattan, and reported that
approximately 7.6% of depressed patients go unrecognized, leading to a missed
opportunity for screening, and this missed opportunity is associated with greater mortality
and reduced quality of life. Several guidelines support recommendations that patients
diagnosed with cancer be routinely screened for the presence of psychological distress,
including depression (Kitchener, et al., 2014). The National Comprehensive Cancer
Network (NCCN) established a panel comprising an interdisciplinary group that
published a guideline recommending that all cancer patients be routinely screened for
distress and psychosocial needs. The panel came up with a broad definition of distress as
a “multifactorial, unpleasant experience of a psychological (i.e., cognitive, behavioral,

41
emotional), social, spiritual, and/or physical nature that may interfere with one’s ability to
cope effectively with cancer, its physical symptoms, and its treatment” (NCCN, 1999).
Distress was described along a continuum to include depression. Three years after the
initial guideline from NCCN, the U.S. National Institutes of Health (NIH) convened a
state-of-the-science conference and recommended that cancer patients be routinely
screened for depression using brief screening tools (National Institutes of Health, 2003).
In 2007, the Institute of Medicine (IOM) released a report that showed that the
psychological needs of cancer patients were not adequately addressed and similar to other
guidelines, recommended that cancer patients be screened for psychological distress
(Institute of Medicine, 2007). Also, routine depression screening of all adults has been
recommended by the U.S. Preventive Services Task Force (USPSTF) since 2009 (Siu et
al., 2016).
Studies have explored the linkage between screening for depression and
appropriate treatment following the screening. There is evidence that depression
treatment in the general population is associated with a better outcome and good response
to treatment (Duval et al., 2006). However, some studies have shown that not all
screening culminates in follow-up care for depression. For example, a study showed that
at six-month follow-up of depression screening in a community health fair, none of the
participants that screened positive for depression and were given a referral made a
follow-up appointment at the community mental health agency (Opperman et al., 2017).
However, it is essential to note that the authors did not factor the fact that some
participants could have followed up with other health care providers outside of the
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referral agency. Indeed, the authors recommended integrating and evaluating the
effectiveness of a brief on-site consultation by mental health professionals to assess any
potential depressive f symptoms fully.
Depression Screening in Cancer Patients
The importance of screening tools in the assessment of depression among patients
with cancer cannot be over emphasized. Depression continues to pose a significant
psychological disruption among cancer patients, especially because it is often
unrecognized and inadequately treated (Caruso et al., 2017). Approximately 50-60% of
cancer patients with depression are unrecognized in clinical practice (Grassi et al., 2010).
In response to the trends in depression recognition and treatment in cancer patients,
several guidelines and screening instruments have been developed (Siu et al., 2016;
Kitchener, et al., 2014). Examples of screening instruments that have been used in
screening depression among cancer patients include:
1. The nine-item Patient Health Questionnaire (PHQ-9)
2. The Distress Thermometer (DT)
3. The Hospital Anxiety and Depression Scale (HADS)
4. The Psychological Distress Inventory
5. The Brief Symptom Inventory
6. The Edinburgh Depression Scale
7. The Zung Self-Rating Depression Scale
8. Single-item interview
9. The Beck Depression Inventory (BDI)
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10. The Hopkins Symptom Checklist (HSCL)
11. Center for Epidemiologic Studies Depression Scale (CES-D)
Wakefield et al (2015) conducted a meta-review of patient-reported depression
measures used in screening depression in the oncology space. This included a review of
more than 50 depression screening measures that are used in patients with any cancer
type. The authors reported that while the HADS was the most widely studied screening
instrument, the wide variability in its recommended cut-points represents an important
limitation to its use. The BDI was notably highlighted as a more generalizable screening
instrument across cancer types and disease stages with greater potential for screening and
case finding. Relative to responsiveness, the Center for Epidemiologic Studies
Depression Scale (CES-D) was reported to be the best-weighted measure.
Several authors have explored the ability of different screening procedures to
detect mood disorders, including depression among cancer patients. For example,
Wagner et al (2017) explored the feasibility, sensitivity, and specificity of commonly
used screening instruments to detect depression among cancer patients receiving
definitive or palliative radiotherapy in community-based radiation oncology settings. The
authors found a good completion rate of the depression screening procedures, indicating
that depression screening in the oncology settings is highly feasible. While comparing the
ability of the PHQ-2, PHQ-9 and National Comprehensive Cancer Network-Distress
Thermometer (NCCN-DT) to detect depression, they concluded that the PHQ-2 is an
effective tool for identifying cancer patients with mood disorders, including depression,
and is comparable to the longer PHQ-9 and superior to the widely used NCCN-DT.
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Other authors have studied the accuracy of depression screening instruments
among specific cancer patients. Katz et al (2004) examined the BDI, the HADS and the
CES-D scale among ambulatory head and neck cancer patients who had received
radiation and who were evaluated for major and minor depression using the Schedule for
Affective Disorders and Schizophrenia (SADS). While all three depression instruments
were reportedly accurate in terms of sensitivity, specificity and positive predictive value
(PPV), the HADS demonstrated the highest level of accuracy and was found to be
potentially most useful. Similarly, the diagnostic accuracy of four different depression
screening instruments (CES-D, BDI-FastScreen, PHQ-9, and a 1-item screener- “Are you
depressed?”) were compared to the gold standard structured Clinical Interview-DSM IV
among ovarian cancer patients undergoing treatment (Shinn et al., 2017). The authors
concluded that the PHQ-9 had the best diagnostic accuracy among the four screening
instruments explored. The CES-D with the traditional cutpoint of 16 and the one-item
screener were the worst methods.
Some authors have explored the degree of agreement between HADS and clinical
assessment outcomes as a function of age, sex, and treatment intention. ThalénLindström et al., (2016) reported a moderate agreement between HADS and clinical
assessment for identifying depression among 146 oncology patients with either curative
or palliative treatment intention. However, the greatest difference between HADS and
clinical assessment was found to be on the basis of age and sex. While agreement was
determined to be better for females compared to males for distress and anxiety,
agreement was better for participants age ≥65 year compared to participants age <65 year
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in relation to depression. Agreement between HADS and clinical assessment was
moderate in relation to whether the treatment intention was curative or palliative.
A variety of cut-off scores have been recommended for each of the depression
screening instruments. The relatively wide variation has led to some degree of challenge
over where to set the threshold for identifying depression cases among cancer patients.
Vodermaier and Millman (2011) conducted a meta-analysis to identify empirically
derived cut-offs for the HADS, which is the most widely validated scale for screening for
emotional distress in cancer patients. The authors reported that the HADS total scale and
HADS depression subscale demonstrated good accuracy for measuring depression,
compared to mental disorders in general. On the HADS total, HADS depression subscale,
and HADS anxiety subscale, they identified a threshold of 15, 7, and 10 or 11,
respectively, as an appropriate cut-off for depression screening.
Several other screening methods have been developed for use in identifying
depression among cancer patients. Most of the assessment methods were developed to
overcome specific challenges peculiar to traditional screening instruments. For example,
the use of a smart phone application for screening for depression could potentially
eradicate the barrier posed by regular screening in patients who rarely visit their
physicians (Kim et al., 2016). Kim et al (2016) conducted the first study that examined
the validity of a mobile app depression screening device among patients with breast
cancer. The authors compared the performance of depression screening using a mobile
mentalhealth tracker with the results from PHQ-9 tests and reported that the two
screening methods where comparable. The expression of certain emotional states,
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including depression, is known to be affected by cultural background, whereby some
cultures do not encourage negative expression considered disruptive (Bae & Park, 2016).
Therefore, the use of depression screening tools that can by-pass the need for patients to
complete questionnaires about their symptoms could be valuable. Kim, et al (2018)
evaluated the use of Diagnostic Drawing Series (DDS) as a screening tool to identify
psychological distress among breast cancer patients, which could supplement the
traditional depression screening questionnaires. The authors concluded that DDS could
be used as a supplemental screening tool to identify psychological distress, including
depression, among breast cancer patients.
Summary
Chapter two represents a synthesis of the information on the screening for
depression among cancer patients in the ambulatory care setting in the U.S. The various
predictors and determinants of depression screening were also reviewed. The prevalence
of cancer and depression and their comorbidity was discussed. A thorough review of the
potential pathophysiology, interaction, and explanation of why depression may co-occur
with cancer was presented. Evidence suggests defective coping mechanisms,
psychological reactions, mere coincidence, and social and biological mechanisms.
A review of the barriers to and access to depression screening guided the
opportunity to explore the potential determinants of depression screening in cancer
patients. The review of the literature uncovered that there is a scarcity of information
regarding the predictors of depression screening specifically among patients diagnosed
with cancer. The extensive review of the historical path of screening and the local and
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international guidelines provided context to the importance of screening and important
criteria to be considered before making decisions on whether to screen for a particular
disease.
Finally, the different depression screening instruments that have been validated
for use in cancer patients were explored. While there are several instruments that have
been validated, the varying cut-offs represent a challenge in deployment among patients.
The HADS is the most widely used, while the PHQ-9 appears to have the best diagnostic
accuracy.
Overall, there is limited to no information on the predictors of depression
screening among cancer patients. The current review explored existing literature but is in
no way exhaustive or conclusive about all the potential predictors. One of the major
findings of the current literature review is the uncovering of a need for further research
work in identifying the predictors of depression screening among cancer patients. The
current research study sought to identify some of the potential predictors of depression
screening using the HBM as the theoretical background. The study analyzed secondary
data from the National Ambulatory Medical Care Surveys (NAMCS). Chapter three
outlines and discusses both the quantitative and the methodological approach needed to
scientifically summarize and analyze the data.
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Chapter 3: Research Method
Introduction
The purpose of this study was to explore and establish the factors that predict
depression screening among cancer patients in the ambulatory care setting in the United
States. Suitable statistical analyses were conducted to determine whether each of the
proposed predictors impacts the likelihood of cancer patients undergoing depression
screening. Several guidelines have recommended depression screening among cancer
patients. This study gives support for that recommendation and for all efforts geared
toward the prompt identification of cancer patients who may require additional treatment
for depression.
This study’s findings may contribute to the development of tailored interventions
targeted at factors in cancer patients that predispose them to not screening for depression.
The correlation between depression and poor cancer survivability has underscored the
need for timely screening for depression accompanied by adequate treatment (Sherrill et
al., 2017). To further explore how depressed cancer patients can be identified more
quickly and get connected to much-needed treatment, I sought in this study to determine
the potential predictors of depression screening among cancer patients. Depression
screening is an important first step toward identifying cancer patients at risk for
depression; therefore, the importance of understanding the determinants of screening
cannot be overemphasized. While there are authors who have explored predictors of
depression screening among the adult population, there are currently no studies in the
literature that have sought information on factors that predict which cancer patients will
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get screened for depression.
In this chapter, I describe the research design and rationale and discuss the study
methodology, including the population and sampling procedures. Potential validity
threats and ethical procedures are also addressed. The chapter concludes with a summary
of all procedures highlighted.
Research Design and Rationale
This study used data from the NAMCS. The NAMCS is a publicly available
national survey conducted by the NCHS of the CDC (NCHS, n.d.-a). The initiative is part
of the National Health Care Survey’s effort to measure healthcare utilization across
various healthcare providers. Specifically, the survey was created to generate objective,
reliable data about the provision and utilization of ambulatory medical care services in
the United States. In this study, I analyzed visits to nonfederally employed, office-based
physicians directly involved in patient care. The category of office-based physicians
excluded radiologists, anesthesiologists, and pathologists. Using the dataset, I specifically
examined those physician visits that involved the exploration of depression screening
among cancer patients.
Research Design
A cross-sectional design was used in this study. The data that I analyzed
originated from the 2014-2016 NAMCS database. The NAMCS database contains
information from an annual probability survey sent to participating nonfederal officebased physicians within the 50 U.S. states and the District of Columbia. The physicians
who took the survey were selected using an intricate sampling design, resulting in a
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systematic random sample of office-based visits. The U.S. Bureau of the Census acts as
the field data collection agent for the NAMCS.
The data collection strategy was designed to minimize data collection workload
and to maintain approximately equal reporting levels among sample physicians,
irrespective of their practice size. The process was achieved through data collection
(performed by the physician or physician’s staff) from 30 randomly selected patient visits
during a randomly assigned, 1-week reporting period (NCHS, n.d.-b). Based on the crosssectional view afforded by the NAMCS dataset, it is scientifically justifiable to identify
independent variables that could potentially predict the independent outcome of
depression screening.
Data Eligibility Criteria
In 2016, the U.S. Preventive Services Task Force (USPSTF) updated its
guidelines to include a recommendation for routine depression screening in patients age
12-18 years (Siu et al., 2016). Rates of depression among adolescents and young adults
with cancer are higher than those in older adults with cancer (Park & Rosenstein, 2015).
Therefore, visits for adolescents were included in the study. Specifically, visits for
patients who were ≥ 12 years of age, with or without depression and with a diagnosis of
cancer, who made an ambulatory care visit to an office-based physician were included in
the study.
Visits were excluded if “yes” was not indicated for the question “Does patient
now have cancer?” Visits to physicians in the anesthesiology, pathology, and radiology
specialties, including designated subspecialties, were also excluded from the study. All
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patient visits that were primarily related to conditions in which depression screening
would be highly unlikely to occur, such as visits related to injuries and for administrative
purposes, were also excluded. It is also important to note that only office-based visits to a
physician were included in the dataset. Federally based physician office visits were not
included in the dataset.
Case Definition
The identification of patients with cancer and depression, and thosewho had
undergone depression screening during ambulatory care visits, was determined based on
the provider’s affirmation in response to specific questions. Cancer ambulatory care visits
were selected if the provider indicated an affirmative response to the question
“Regardless of the diagnosis previously entered, does the patient now have cancer?” The
event was recorded irrespective of the list of diagnoses related to the current visit.
Cancer included any cancer type and was generally not limited to any specific
body site. Similarly, depression was identified whenever the provider checked the box
corresponding to the question “Regardless of the diagnosis previously entered, does the
patient now have depression?” During a visit, the provider marked all services, including
examination and screening, provided during that visit. In the NAMCS database,
depression screening was dichotomized with a yes/no response. No specific depression
screening type or procedure was identified. There was also a section on the NAMCS
patient record designated as “providers.” The type of provider seen at the visit was
indicated, with possible selections including physician, physician assistant, nurse
practitioner/midwife, RN/LPN, mental health provider, other, and none.
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Additionally, the patient’s age (in years, months, and days), sex, and race were
collected. For this study, age, sex (defined as male or female), race (defined as White,
Black or African American, Asian, Native Hawaiian or Other Pacific Islander, or
American Indian or Alaska Native), and physician specialty represented the independent
variables, while depression screening was the dependent variable. Geographic regions
included Northeast, Midwest, South, and West.
Methodology
Population
The number of new cancer cases worldwide has been projected to reach
approximately 26 million, with 17 million cancer deaths per year by 2030 (Thun et al.,
2010). In the United States, close to 2 million new cases of cancer have been estimated to
occur in 2020, with approximately 34% of those patients expected to die in 2020 (Siegel
et al., 2020). The prevalence of depression among newly diagnosed patients and patients
chronically affected by cancer is significant (Wagner et al., 2017; Walker et al., 2013).
Depression screening has been recommended to identify cases promptly and connect
patients with treatment (Siu et al., 2019).
For this dissertation, the study population included patients visiting the
ambulatory care setting in the United States with a cancer diagnosis. The NAMCS
captures nationally representative healthcare services provided in ambulatory care
settings in the United States. Surveys are administered cross-sectionally to record
physician-patient encounters or visits. For the purpose of the survey, a visit was defined
as “a direct, personal exchange between a physician, or a staff member operating under a
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physician’s direction, for the purpose of seeking care and rendering health services”
(NCHS, 2017a). The study sample included both male and female patients 12 years of
age and above who reported a diagnosis of cancer at an ambulatory care visit.
Sampling and Sampling Procedures
Sampling Strategy
Secondary data were drawn from 3 consecutive years of the NAMCS (i.e., from
2014 to 2016). These data pertained to depression screening among patients with a
current diagnosis of cancer. The survey response rates for physician-level responses for
the core NAMCS samples covered in this study in 2014, 2015, and 2016 were 54.8%,
46.0%, and 46.0% (weighted), respectively. The sampling design of the NAMCS consists
of a cross-sectional, multistage probability survey of visits to office-based physicians. A
stratified two-stage sample in which physicians were selected in the first stage and visits
were selected in the second stage was used as the sampling design. The American
Medical Association and American Osteopathic Association maintained the master files
from which a stratified sample list of physicians was selected.
Each of the sampling strata was defined by census region and physician specialty
group. The census regions included Northeast, Midwest, South, and West. The 15
physician specialties that were included were as follows:


general and family practice,



osteopathy,



internal medicine,



pediatrics,
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obstetrics and gynecology,



general surgery,



orthopedic surgery,



cardiovascular diseases,



dermatology,



urology,



psychiatry,



neurology,



ophthalmology,



otolaryngology, and



a residual category for all other specialties.

Dataset Access
This study used the NAMCS dataset. The NCHS offers the NAMCS data as freely
downloadable, public-use data files through the CDC FTP file server. Permission is not
required to download the data. The service is freely available to users, and appropriate
datasets, documents, and questionnaires from NCHS surveys, including all data
collection procedures, can be downloaded. Instructions for downloading files are
provided on the website in “readme” files. The data are available in self-extracting,
compressed data files. Data extraction is complete after downloading the data. All that is
therefore needed to access the dataset is access to the internet. The dataset is available for
download to be used with various statistical software, including SAS, STATA, and SPSS.
I downloaded 2014 through 2016 survey data that were saved in SPSS format.
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Power Analysis
An essential aspect of study design is sample size calculation. The sample size
refers to the number of study participants who need to be enrolled in a research study to
detect a clinically significant treatment effect. Simply put, sample size is the number of
participants in a sample (Kadam & Bhalerao, 2010). While a study with an inadequate
sample size may make it difficult to detect any meaningful effect, having too many
respondents included in a sample may impact the results of a research study by producing
a statistically significant yet clinically insignificant result (Hickey et al., 2018). This
important methodological concept underscores the importance of appropriately
calculating the sample size at the study design stage of a research project.
To determine the sample size for this study, I utilized the computer software
G*Power 3.1 (Faul et al., 2009). This software is available for free download and
installation and has an intuitive interface that eliminates unnecessary complications
related to sample size determination. There are two crucial points that users must note
before conducting sample size calculation using this software:
1. The researcher must determine the right statistical test to use.
2. The researcher must understand what the predictor variables are.
The software allows the user to choose a statistical test; for this study, I chose
logistic regression. Logistic regression aligned with my research question, with a
dichotomous dependent variable and both binary and continuous independent variables.
The odds ratio option was selected for entering the expected effect size. The study tested
whether different independent variables (e.g., sex as a dichotomous variable) were
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significant predictors of a binary outcome variable. In the G*Power software, two tails
were chosen, and for test family and statistical test, the z test and logistic regression were
selected. The power calculation was based on the assumption that for gender, women and
men with cancer will have a 50% and 30% probability of being screened for depression,
respectively. The error probability was set at 0.05, and to be able to demonstrate an
association between the independent and dependent variables, given that an association
exists, the power was set at 0.95. Based on these parameters, the sample size was set at
312. Figure 1 shows the G*Power calculation.
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Figure 1
Sample Size Calculation Using G*Power 3.1
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Instrumentation and Operationalization of Constructs
NAMCS was launched in 1973 and developed as a product of more than six years
of intensive research aimed at determining the feasibility of the survey and testing
alternative methods for conducting the survey (NCHS, 1988). There has not been an
extensive independent effort to validate the instruments used in the NAMCS surveys.
Since the beginning of the surveys' deployment, there have been only a few studies that
have examined the validity of the questionnaires used in NAMCS. Gilchrist et al. (2004)
compared the NAMCS measurement approach with direct observation of outpatient
visits, including office visits of 549 patients visiting 30 family physicians. As observed
by trained research nurses, the visits were compared with data reported by physicians
during the 1993 NAMCS survey deployment. While there was generally a good
concordance between the NAMCS method and direct observation method for reports of
procedures and examinations (including screening procedures), this was not the case for
health behavior counseling. The result showed that reports from NAMCS may be more
accurate for procedures and examination than for health behavior counseling. However,
since its inception, the NAMCS has been a source of good data to describe U.S. primary
care. There is evidence that the method of survey used is well established and provides
nationally representative information on physician office visits (NCHS, n.d.-a).
While most of the surveys were completed either through a paper instrument or
electronically through the web-based instrument, it is important to note that three
different methods were used in collecting the data; namely, through a self-administered
web-based instrument completed electronically, a paper instrument that was self-
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administered and subsequently returned via mail, and the use of a computer-assisted
telephone interview. The physicians selected in the sample were initially contacted by
mail, in which a brief description of the survey was conveyed, and they were asked for
their participation. In the next phase, field representatives contact the physicians by a
phone call to set up an appointment for an in-office visit. At the in-office stage, the
survey is explained more extensively, and approval to participate in the survey sought.
For the physicians that agree to participate, a week is randomly assigned for the team to
complete the survey, after which the physician mail the finished survey to the field
representative. Data are collected using the patient log and the patient record.
Data Analysis Plan
This study's data source was the NAMCS, a national probability sample survey of
visits to office-based physicians and community health centers conducted by the NCHS.
IRB approval was sought and received before analyzing the dataset. The primary
outcome variable was depression screening (yes/no). Independent variables that were
explored include consultation with a mental health provider, time spent with the
physician, gender, age, and race of patient, and physician specialty. Each of the
independent variables were examined to determine if they served as predictors of
depression screening in cancer patients during regular office visits with a physician.
SPSS 25 was the statistical package that was used for all data analyses. The
means or the relative frequencies or proportions and the standard errors (SE) of the
independent variables were reported. To test whether the independent variables can
predict the dependent variable, I performed a logistic regression analysis. The logistic
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regression is the appropriate regression analysis to perform to determine or describe the
relationship between a qualitative dependent variable that takes the form of a
dichotomous variable and an independent variable. It can compute the odds ratio in the
context of greater than one exploratory variable (Sperandei, 2014). Its use of a binomial
response variable represents one of the main differences between it and multiple linear
regression. In this study, the dependent variable were dichotomized, while the
independent variables included both categorical variables such as gender and race, and
continuous variables such as age. This approach aligns well with analyzing the dataset
using logistic regression. Where appropriate, I presented the odds ratios (ORs), 95%
confidence intervals (CIs), and the P values. Statistical significance was set at p<0.05. As
part of the strategy to emphasize any signals in the data while excluding all potential
"noise," I conducted data preparation to include recoding, assessing for variable
reconstruction, and handling missing data (Kang, 2013).
Coding of Responses
All the responses from the NAMCS dataset in SPSS were coded appropriately to
fit logistic regression analysis. All dichotomous variables were assigned a code of 0 and
1. For example, the value “0” was used to code for a “no” or similar response, while the
value “1” was assigned to all responses that are “yes” or similar. For continuous
independent variables, higher value represents more of the variable of interest.
Missing Data
My approach to handing missing data is described next. The tendency for
introducing bias to subsequent statistical analyses when the missing data are greater than
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10% is valid (Bennett, 2011). I explored all the main variables that were included in the
analysis for missing data and logical inconsistencies. The skip pattern and section flow
were examined in order to check for structural missing versus missing due to “refusal” or
“don’t know” responses. The mean replacement method or the median replacement
method in SPSS were used for missing data. When non-response occurs at an individual
level, I made a decision on whether the data will be used or excluded.
The Data Dictionary
The data dictionary is discussed in this section for the purpose of defining the
scope and characteristics of data elements used for analysis, and applicable rules that
govern their application. Some examples of variables that are contained in the data
dictionary for the research are presented in Table 1.
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Table 1
Data Dictionary
Column name
DEPRN

Column
type
Numeric

Column
width
1

DEPRESS

Numeric

CANCER

Column description
Does patient now have:
Depression

Measure
Unknown

1

Depression screening

Unknown

Numeric

1

Does patient now have:
Cancer

Unknown

Age

Numeric

3

Patient age in years

Unknown

SEX

Numeric

1

Patient sex

Unknown

MHP

Numeric

1

Mental health provider
seen

Unknown

TIMEMD

Numeric

3

Time spent with physician
in minutes

Unknown

RACER

Numeric

1

Patient race—imputed

Unknown

SPECR

Numeric

2

Physician specialty—14
groups

Unknown

REGIONOFF

Numeric

1

Region where majority of
physician’s sampled visits
occurred

Unknown
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Research Questions and Hypotheses
RQ1. Is there an association between consultation with a mental health provider
and screening for depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
RQ2. Is there an association between time spent with the physician and
screening for depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
RQ3. Is there an association between gender and screening for depression
among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
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Alternative hypothesis (HA): There is a statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
RQ4. Is there an association between age and screening for depression among
patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between age and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant
association between age and screening for depression among
patients with a diagnosis of cancer.
RQ5. Is there an association between race and screening for depression among
patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
RQ6. Is there an association between physician specialty and screening for
depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
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between physician specialty and screening for depression among
patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between physician specialty and screening for depression among
patients with a diagnosis of cancer.
Threats to Validity
It is worth noting some potential threats to validity, both internal and external,
related to this study. Internal and external validity are indicative of the instruments'
properties, including questionnaires or surveys, and the population selected and used to
collect data. Both concepts generally refer to a lack of systematic error. A pictorial
representation of the concept of study validity is depicted in Figure 2.
Figure 2
Schematic Representation of Validity

Internal Validity
The avoidance of major methodological problems and studies free from biases are
the hallmarks of research with high internal validity.
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Selection bias: The NAMCS uses a sophisticated, well-planned, three-stage,
stratified cluster design in selecting participating respondents. For example, in the first
stage, the primary sampling unit is selected with a probability proportional to population
size and consists of identifying the county or group of counties of interest. The second
stage is selected based on a probability inversely proportional to the number of
physicians in the primary sampling unit. The third stage is selected based on the visits to
a physician’s office. The three-stage, stratified cluster design ensures that there is no
selection bias in terms of selecting participants for the survey. Also, while the sampling
plan does not necessarily guarantee that all physicians and physician visits are sampled, it
does ensure a reasonable representation.
External Validity
The ability to apply the results obtained from this study to a population broader
than the one used in the study is referred to as external validity or generalizability (Patino
& Ferreira, 2018). Therefore, it is crucial to consider the extent to which the respondents
studied are representative of the more general population. Typically, this is done by
characterizing and comparing those who did not participate in the study with those who
did participate to identify any differences.
For the study, I analyzed secondary data from the NAMCS dataset, which has an
intricate survey design. Ward (2018) extensively demonstrated the impact of using
inappropriate methods of estimation, known as an analytic error, in analyzing survey data
from a complex survey design such as the NAMCS dataset and its effect on the
generalizability of results. Specific examples include not applying data weights,
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overlooking the foundational complexity of survey design, and deficiently subsetting data
during subpopulation analysis. A proper understanding of the survey data and the use of
the appropriate estimation techniques will go a long way as part of the strategies to
mitigate the problem.
Ethical Procedure
The secondary dataset used in the study is from NAMCS, which is a freely
available public dataset. The survey is administered by the NCHS, which is legally
responsible for ensuring the confidentiality of all responses. This includes all potential
data collected that may result in a physician or hospital being de-identified. Therefore, all
information released publicly and used for research does not include any provider or
patient identifying information. The survey data generally describes the characteristics of
visits to ambulatory care services and may consist of data elements such as patient
demographic characteristics, patients’ condition most often treated, and the diagnostic
procedures and treatment that was given. Researchers intending to use NAMCS are
expected to comply with data use restrictions to ensure that all information obtained from
the dataset are used only for statistical analysis or reporting purposes. The data use
restrictions agreement is available at
https://www.cdc.gov/nchs/data_access/restrictions.htm. Therefore, the following efforts
were made to ensure the confidentiality of individuals and establishments included in the
dataset:


All datasets downloaded from NCHS were used for statistical analysis only.



No attempt was made to identify respondents included in the dataset.
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The dataset was not linked with individually identifiable data from other
NCHS or non-NCHS datasets.



I did not engage in any activity with the intention of re-identifying individuals
and establishments included in the dataset.

Furthermore, the Walden university Internal Review Board (IRB) is tasked with
ensuring that all research conducted in the University follows the Walden University’s
ethical standards and U.S. federal regulations. Prior to the analysis of the secondary data,
approval was obtained from the Walden University IRB. In case there is a need for a third
party to review the dataset, I ensured they were trained in human subject research and
Health Insurance Portability and Accountability Act (HIPAA) regulations before giving
them access to the dataset. Any deviation to the research plan was planned to be promptly
reported to the Walden University IRB.
Summary
In this chapter, I discussed extensively the research design. The variables that will
be used were discussed concisely. A thorough review of the methodology, including the
population, sampling, and sampling procedures, was presented. The sampling frame,
including the eligibility criteria, as well as the power analysis, were highlighted. The
instrumentation and operationalization of the survey to be used were also discussed.
Finally, I transitioned to discussions related to validity threats and ethical procedures
involved in the conduct of the research. In Chapter four, I present the results of the
analysis of the secondary dataset.
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Chapter 4: Results
Introduction
In this chapter, I summarize the results of the analyses performed. The logistic
regression was used to determine whether there was any predictive association between
the independent and dependent variables. Specifically, the study used the logistic
regression to explore whether consultation with a mental health provider; time spent with
the physician; patient gender, age, and race; and physician specialty were predictors of
depression screening among patients with cancer attending ambulatory healthcare
settings in the United States. To further investigate the effects of other potential
predictors, additional post hoc analyses were conducted, and results are presented in this
section.
The purpose of this research was to determine and evaluate the predictors of
depression screening among cancer patients in ambulatory care settings in the United
States. This work contributes to the body of literature by increasing knowledge about
determinants of depression screening among cancer patients related to crucial patient and
physician characteristics. The study may also stimulate new approaches to recognizing
and managing patients with comorbid conditions and informing public debates, policymaking strategies, and screening guidelines.
Research Questions and Hypotheses
RQ1. Is there an association between consultation with a mental health provider
and screening for depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
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between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between consultation with a mental health provider and screening
for depression among patients with a diagnosis of cancer.
RQ2. Is there an association between time spent with the physician and
screening for depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between time spent with the physician and screening for
depression among patients with a diagnosis of cancer.
RQ3. Is there an association between gender and screening for depression
among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between gender and screening for depression among patients with
a diagnosis of cancer.
RQ4. Is there an association between age and screening for depression among
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patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between age and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant
association between age and screening for depression among
patients with a diagnosis of cancer.
RQ5. Is there an association between race and screening for depression among
patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between race and screening for depression among patients with a
diagnosis of cancer.
RQ6. Is there an association between physician specialty and screening for
depression among patients with a diagnosis of cancer?
Null hypothesis (H0): There is no statistically significant association
between physician specialty and screening for depression among
patients with a diagnosis of cancer.
Alternative hypothesis (HA): There is a statistically significant association
between physician specialty and screening for depression among
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patients with a diagnosis of cancer.
Data from the NAMCS comprising a national probability sample of visits to the
emergency and outpatient departments of noninstitutional general and short-stay hospitals
were accessed and analyzed to answer the research questions. The NAMCS consists of
nationally representative data about outpatient practice in the United States. In this
chapter, I present the results of the statistical analysis of the NACMS secondary dataset
comprising merged datasets from 2014 through 2016. In the subsequent sections, I
describe both the descriptive and inferential analyses. The chapter concludes with a
summary, including a transitional summary that leads to this project’s final chapter.
Results
The 2014–2016 NAMCS datasets included 87,207 ambulatory care visits. A total
of 7,146 visits by patients age 12 years and above who were diagnosed with cancer met
the study inclusion criteria. Depression was reported at 9% of visits. Depression
screening occurred during 3.8% of the community-based physician practice visits. Key
predictor characteristics were summarized by categorical and continuous variables.
Summaries included mean, standard deviation, minimum and maximum for continuous
variables, and counts/frequencies and percentages for categorical variables. Information
about the categorical variables for the population is provided in Tables 1–5, and
information about the continuous variables is provided in Table 6.
The age variable was subdivided into five categories: (a) 12-22 years, (b) 23-42
years, (c) 43-62 years, (d) 63-72 years, and (e) 73 years and older (Table 2). Physician
visits involved patients who were predominantly 73 years and older (39.3%). Patients in
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the age groups 12-22, 23-42, 43-62, and 63-72 accounted for 30 (0.4%), 331 (4.6%),
1,823 (25.5%), and 2,154 (30.1%) physician visits, respectively. Figure 3 shows the
clustered bar percentage of depression screening by age group. Patients in the age groups
63-72 and 73 and older were more likely to be screened for depression during physician
office visits.
Table 2
Frequencies and Percentages of Patient Visits by Patient Age Group
Age group (years)
12-22
23-42
43-62
63-72
73 and older
Total

Frequency (n)
30
331
1823
2154
2808
7146

Figure 3
Clustered Bar Percent of Depression Screening by Age Group

Percent (%)
0.4
4.6
25.5
30.1
39.3
100.0
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In terms of gender, more physician visits involved male patients, accounting for
3,641 (51%) visits (Table 3). The association between gender and depression screening
was examined using the clustered bar chart in Figure 4, which shows that only 1.69% of
male patient visits included screening for depression, while 2.14% of female patient visits
included depression screening.
Table 3
Frequencies and Percentages of Patient Visits by Patient Gender
Gender

Frequency

Percent

Male

3,641

51.0

Female

3,505

49.0

Total

7,146

100.0

Figure 4
Clustered Bar Percent of Depression Screening by Gender
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Table 4 shows the frequencies and percentages of the racial/ethnic group
categories. The race variable was subdivided into four categories: (a) Non-Hispanic
White, (b) Non-Hispanic Black, (c) Hispanic, and (d) Non-Hispanic Other. Physician
visits involved patients who were predominantly Non-Hispanic White, accounting for
6,201 (86.8%) visits. Physician visits were somewhat comparable for the other
racial/ethnic groups and accounted for 434 (6.1%), 352 (4.9%), and 159 (2.2%) for NonHispanic Blacks, Hispanics, and Non-Hispanic Other, respectively. Association between
racial/ethnic groups and depression screening was examined using a clustered bar chart.
Similar to Table 4, Figure 5 shows that most physician visits that included a depression
screening occurred among Non-Hispanic Whites (3.29%), compared to 0.20%, 0.27%,
and 0.08% seen in the categories Non-Hispanic Black, Hispanic, and Non-Hispanic
Other, respectively.
Table 4
Frequencies and Percentages of Patient Visits by Patient Race/Ethnicity
Ethnic groups/total

Frequency

Percent

Non-Hispanic White

6,201

86.8

Non-Hispanic Black

434

6.1

Hispanic

352

4.9

Non-Hispanic Other

159

2.2

7,146

100.0

Total
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Figure 5
Clustered Bar Percent of Depression Screening by Race/Ethnicity

Furthermore, most physician visits, accounting for 1,816 (25.4%), were to
physicians identified as having other specialties. Visits to dermatologists, urologists, and
family physicians accounted for 1,146 (16.0%), 1,084 (15.2%), and 565 (7.9%),
respectively, as shown in Table 5. The association between physician specialty and
depression screening was also examined using a clustered bar chart. Figure 6 shows that
depression screening was completed more among physicians with other specialties
(1.39%), followed by primary care physicians (0.66%), internists (0.50%), and urologists
(0.38%).
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Table 5
Frequencies and Percentages of Patient Visits by Physician Specialty
Frequency
565
423
25
508

Percent
7.9
5.9
.3
7.1

Obstetrics and gynecology

168

2.4

Orthopedic surgery
Cardiovascular diseases
Dermatology
Urology
Psychiatry
Neurology
Ophthalmology
Otolaryngology
Other specialties
Total

246
251
1146
1084
51
132
366
365
1816
7146

3.4
3.5
16.0
15.2
.7
1.8
5.1
5.1
25.4
100.0

General/family practice
Internal medicine
Pediatrics
General surgery
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Figure 6
Clustered Bar Percent of Depression Screening by Physician Specialty

In terms of ambulatory visits involving consultation with a mental health
provider, physician visits involved predominantly patients who did not consult with a
mental health provider, accounting for 7,126 (99.7%) visits, as shown in Table 6. The
association between consultation with a mental health provider and the outcome variable
was examined using a clustered bar chart. Figure 7 shows that within the group that
consulted with a mental health provider, only 0.03% of visits included screening for
depression. In comparison, 3.81% of physician visits had depression screening among
patients who did not consult with a mental health provider.
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Table 6
Frequencies and Percentages of Patient Visits by Mental Health Provider Seen
Frequency

Percent

No

7,126

99.7

Yes

20

.3

Total

7,146

100.0

Mental health provider seen

Figure 7
Clustered Bar Percent of Depression Screening by Consultation With Mental Health
Provider
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Univariate Descriptive Statistics for Continuous Variables
The continuous variable was summarized by tabulations of n, mean, range,
standard deviation, maximum, and minimum. The only continuous variable included in
the analysis is “the time spent with physician.” The variable was measured in minutes,
with the minimum and maximum time spent being zero and 90 minutes, respectively. The
mean time spent with a physician was 23.23 minutes with a standard deviation of 14.214.
Table 7 shows the descriptive statistics for the continuous variables included in the
analyses.
Table 7
Descriptive Statistics for Time Spent With Physician

Time spent with
physician in minutes
Valid N (listwise)

N

Range

7,146

90

Minimu
Maximum
m
0

90

Mean

Std.
deviation

23.23

14.214

7,146

Univariate Logistic Regression
Logistic regression was used to assess how well the set of predictor variables
predicted or explained the categorical dependent variable of screening for depression
(yes/no). The specific individual effect of each of the predictor variables on the outcome
variable and the amount of variance explained by each predictor variable was explored.
Simple logistic regression was performed for each of the research questions.
Research Question 1
The first research question explored whether there is an association between
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consultation with a mental health provider and screening for depression among patients
with a diagnosis of cancer. Simple logistic regression was performed to assess the impact
of consultation with a mental health provider among patients with a cancer diagnosis on
the likelihood that they will have a depression screening during that visit. Variables
with p-values less than 0.05 represent those that contributed significantly to the predictive
ability of the model. The full model containing the predictor (i.e., consultation with a
mental health provider) was not statistically significant, χ² (1, N=7146) = 1.455, p=0.228,
indicating that the model was not significantly better than the baseline model (i.e., the
result of the analysis with only the dependent variable). The model explained between
0.0% (Cox and Snell R square) and 0.001% (Nagelkerke R squared) of the variance in
depression screening and correctly classified 96.2% of cases. Table 8 shows that
consultation with a mental health provider failed to make a unique, statistically
significant contribution to the model. The odds ratio was 2.8. This implies that patients
who consulted with a mental health provider during an ambulatory visit were almost
three times as likely to report screening for depression as those who did not consult a
mental health provider. However, this was not statistically significant (p=0.169). This is
evidenced by a 95% CI that ranged between 0.646 and 12.127. Based on the findings, I
did not reject the null hypothesis.
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Table 8
Logistic Regression: Consultation With a Mental Health Provider as a Predictor of
Depression Screening

B
Mental health
Step 1

a

provider seen (1)
Constant

a

SE

Wald

df

Sig.

Odds
ratio

1.030

.748

1.895

1

.169

2.800

-3.227

.062

2724.002

1

.000

.040

95.0% CI for odds
ratio
Lower

Upper

.646

12.127

Variable(s) entered on Step 1: Mental health provider seen.

Research Question 2
The second research question explored whether there is an association between
time spent with the physician and screening for depression among patients with a
diagnosis of cancer. Simple logistic regression was performed to assess the impact of
time spent with the physician among patients diagnosed with cancer on the likelihood
that they had a screening for depression completed during that physician's office visit.
The full model containing time spent with the physician as a predictor was not
statistically significant, χ² (1, N=7146) = 2.061, p=0.151, indicating that the model was
not significantly better than the baseline model (i.e., the result of the analysis with only
the dependent variable). The model as a whole explained between 0.0% (Cox and Snell R
square) and 0.00% (Nagelkerke R squared) of the variance in depression screening and
correctly classified 92.2% of cases. Table 9 shows that "time spent with the physician"
failed to make a unique statistically significant contribution to the model. The odds ratio
was 1.006. This implies that for every unit increase in time spent with a physician during
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an ambulatory visit, the odds of screening for depression increased by 0.6%. This
relationship was not statistically significant, as evidenced by a 95% CI that ranged
between 0.998 and 1.014. Based on the findings, I did not reject the null hypothesis.
Table 9
Logistic Regression: Time Spent With Physician as a Predictor of Depression Screening

B
Time spent with
Step 1

a

physician in minutes
Constant

a

SE

Wald

df

Sig.

Odds
ratio

.006

.004

2.177

1

.140

1.006

-3.362

.115

850.706

1

.000

.035

95.0% CI for odds
ratio
Lower

Upper

.998

1.014

Variable(s) entered on Step 1: Time spent with physician in minutes.

Research Question 3
The third research question explored whether there is an association between
patient gender and screening for depression among patients with a diagnosis of cancer.
Simple logistic regression was performed to assess the impact of gender among patients
diagnosed with cancer on the likelihood that they were screened for depression. The full
model containing gender as the predictor was statistically significant χ² (1, N=7146) =
5.265, p = 0.02, indicating that the model could distinguish between patients who had a
screening for depression and those that did not. The model explained between 0.1% (Cox
and Snell R square) and 0.3% (Nagelkerke R squared) of the variance in depression
screening and correctly classified 96.2% of cases. As shown in Table 10, gender made a
unique, statistically significant contribution to the model. The odds ratio of 1.328 implies
that female cancer patients were 1.3 times as likely to report screening for depression as
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their male counterparts. This finding was statistically significant (p = 0.02, odds
ratio=1.328, CI=1.041-1.693). Based on the findings, the null hypothesis was rejected.
Table 10
Logistic Regression: Gender as a Predictor of Depression Screening

B

Step 1a
a

Patient sex(1)
Constant

SE

Wald

df

Sig.

Odds
ratio

.284

.124

5.227

1

.022

1.328

-3.370

.092

1328.853

1

.000

.034

95.0% CI for odds
ratio
Lower

Upper

1.041

1.693

Variable(s) entered on Step 1: Patient sex.

Research Question 4
The fourth research question explored whether there was an association between
patient age and screening for depression among patients with a diagnosis of cancer.
Simple logistic regression was performed to assess the impact of patient age among
patients with a cancer diagnosis on the likelihood of being provided with screening for
depression. The full model containing age as a predictor was not statistically significant
χ² (4, N=7146) = 3.789, p = 0.435, indicating that the model was not significantly better
than the baseline model (i.e., the result of the analysis with only the dependent variable).
The model explained only between 0.1% (Cox and Snell R square) and 0.2% (Nagelkerke
R squared) of the variance in depression screening and correctly classified 96.2% of
cases. Table 11 shows that none of the age groups were significant predictors of
screening for depression. Based on the findings, the null hypothesis was not rejected.
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Table 11
Logistic Regression Showing Age as a Predictor of Depression Screening

B

SE

Age group

Step 1a

df

Sig.

3.862

4

.425

ratio

95.0% CI for odds
ratio
Lower

Upper

Age Group(1)

.387

1.049

.136

1

.712

1.473

.189

11.509

Age Group(2)

.086

1.025

.007

1

.933

1.089

.146

8.119

Age Group(3)

.280

1.023

.075

1

.784

1.323

.178

9.819

Age Group(4)

.037

1.022

.001

1

.971

1.038

.140

7.696

-3.367

1.017

10.961

1

.001

.034

Constant
a

Wald

Odds

Variable(s) entered on Step 1: Age group.

Research Question 5
The fifth research question explored whether there was an association between
patient race and screening for depression among patients with a diagnosis of cancer.
Simple logistic regression was performed to assess the impact of race among patients
with a cancer diagnosis on the likelihood of being provided with screening for
depression. The full model containing race as a predictor was not statistically significant
χ² (3, N=7146) = 2.574, p = 0.462, indicating that the model was not significantly better
than the baseline model (i.e., the result of the analysis with only the dependent variable).
The model explained between 0.0% (Cox and Snell R square) and 0.01% (Nagelkerke R
squared) of the variance in depression screening and correctly classified 96.2% of cases.
Table 12 shows that none of the racial groups were significant predictors of screening for
depression. Based on the findings, I did not reject the null hypothesis.
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Table 12
Logistic Regression Showing Race as a Predictor of Depression Screening

B

SE

Race/ethnicity—
Imputed
Race/ethnicity—
Imputed(1)
Step 1a Race/ethnicity—
Imputed(2)
Race/ethnicity—
Imputed(3)
Constant
a

Wald

df

Sig.

2.773

3

.428

Odds
ratio

95.0% CI for odds
ratio
Lower

Upper

-.167

.280

.356

1

.551

.846

.489

1.464

.371

.245

2.286

1

.131

1.449

.896

2.342

-.004

.421

.000

1

.992

.996

.436

2.274

-3.234

.067

2365.024

1

.000

.039

Variable(s) entered on Step 1: Race/ethnicity—Imputed.

Research Question 6
The sixth research question explored whether there was an association between
physician specialty and screening for depression among patients with a diagnosis of
cancer. Simple logistic regression was performed to assess the impact of physician
specialty among patients with a cancer diagnosis on the likelihood of being screened for
depression. The model contained one predictor variable (physician specialty). The full
model containing the predictor variable was statistically significant χ² (13, N=7146) =
161.273, p < .001, indicating that the model was able to distinguish between patients who
had a screening for depression and those that did not. The model explained between 2.2%
(Cox and Snell R square) and 8.0% (Nagelkerke R squared) of the variance in depression
screening and correctly classified 96.2% of cases. Table 13 shows that physician
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specialty was significantly associated with receipt of depression screening. The odds of
receiving screening for depression were higher among patients that saw their primary
care physicians than among patients that saw their physicians in general surgery,
orthopedic surgery, cardiovascular disease, dermatology, urology, ophthalmology, and
otolaryngology, and others (p <0.01).
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Table 13
Logistic Regression Showing Physician Specialty as a Predictor of Depression Screening
B

SE

Physician specialty—14
groups

Wald

df

Sig.

114.790

13

.000

Odds

95.0% CI for odds ratio

ratio

Lower

Upper

Physician specialty—14
groups (internal

.025

.231

.012

1

.914

1.025

.651

1.614

-.043

.753

.003

1

.955

.958

.219

4.191

-1.093

.303

12.990

1

.000

.335

.185

.607

-.472

.375

1.583

1

.208

.624

.299

1.301

-1.703

.527

10.455

1

.001

.182

.065

.511

-1.496

.477

9.848

1

.002

.224

.088

.570

-2.847

.437

42.498

1

.000

.058

.025

.137

-1.268

.247

26.256

1

.000

.282

.173

.457

.718

.414

3.007

1

.083

2.050

.911

4.617

-.215

.377

.325

1

.569

.806

.385

1.690

-2.804

.725

14.951

1

.000

.061

.015

.251

-1.877

.475

15.587

1

.000

.153

.060

.389

medicine)
Physician specialty—14
groups (pediatrics)
Physician specialty—14
groups (general surgery)
Physician specialty—14
groups (obstetrics and
gynecology)
Physician specialty—14
groups (orthopedic
Step 1a

surgery)
Physician specialty—14
groups (cardiovascular
disease)
Physician specialty—14
groups (dermatology)
Physician specialty—14
groups (urology)
Physician specialty—14
groups (psychiatry)
Physician specialty—14
groups (neurology)
Physician specialty—14
groups (ophthalmology)
Physician specialty—14
groups (otolaryngology)
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Physician specialty—14
groups (other specialties)
Constant
a

-.453

.184

6.065

1

.014

.635

-2.400

.152

248.164

1

.000

.091

.443

.912

Variable(s) entered on Step 1: Physician specialty—14 groups.

Additional Analyses
Additional analyses were performed to characterize and explore potential
predictors of depression screening among patients diagnosed with cancer. Another
rationale for including these analyses was based on the increasing evidence that
physicians' region of practice appeared to contribute as an important determinant of
health care services provision (Bhattacharjee et al., 2018; Harrison et al., 2010). These
analyses, though not defined a priori, are included in this section. Specifically, an
additional analysis was performed to investigate the relationship between the region
where physicians’ visits occurred, and the probability of screening for depression. The
variable consisted of four categories, including Northeast, Midwest, South, and West.
Table 14 depicts the frequencies and percentages of the regions where most physicians’
sampled visits occurred. Most visits occurred in the Midwest and South, accounting for
30.8% and 31.9%, respectively, of the total visits.
Table 14
Frequencies and Percentages of Geographic Region
Geographic region
Northeast

Frequency
1014

Percent
14.2

Midwest

2199

30.8

South

2278

31.9

West

1655

23.2

90
Total

7146

100.0

Simple logistic regression was performed to assess whether region was a predictor
of depression screening. The full model containing region as a predictor was statistically
significant χ² (3, N=7146) = 11.533, p = 0.009, indicating that the model was able to
distinguish between patients who received and those who did not receive screening for
depression. The model explained between 0.2% (Cox and Snell R square) and 0.6%
(Nagelkerke R squared) of the variance in depression screening and correctly classified
96.2% of cases. Table 15 shows that cancer patients who had physician visits in the
Northeast region were approximately twice as likely to be screened for depression as
those having visits in the Midwest (OR=2.074, CI=1.311-3.283, P=.002), 1.8 times as
likely to be screened for depression as those having visits in the West (OR=1.818,
CI=1.125-2.939, P=.002), and 1.6 times as likely to be screened for depression as those
having visits in the South.
Table 15
Logistic Regression Showing Region as a Predictor of Depression Screening

B

SE

Wald

df

Sig.

Odds
ratio

95% CI for odds
ratio
Lower

Upper

1.311

3.283

Region where majority
of physician's sampled
Step 1a

10.325

3

.016

9.702

1

.002

visits occurred
Region where
physicians’ visits
occurred (Midwest)

.730

.234

2.074
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Region where
physician's visits

.488

.239

4.181

1

.041

1.629

1.020

2.601

.598

.245

5.950

1

.015

1.818

1.125

2.939

-3.763

.211

318.334

1

.000

.023

occurred (South)
Region where
physician's visits
occurred (West)
Constant
a

Variable(s) entered on Step 1: Region where majority of physician's sampled visits occurred.

Additionally, multivariate logistic regression was performed. The findings were
consistent with the univariate analyses in which physician specialty and geographical
region where physician visits occurred were significantly associated with receipt of
depression screening. However, when the other variables were controlled for, gender,
which was a statistically significant predictor of depression screening among cancer
patients on its own, was no longer significant, implying a potential confounder interaction
(OR=1.048, CI=0.803-1.368, P=.729).
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Table 16
Multivariate Logistic Regression Predicting Likelihood of Receipt of Depression

a

Step 1

B

SE

Wald

df

Sig.

Mental health provider seen (1)

.064

.781

.007

1

Time spent with physician in minutes

.000

.004

.007

Patient sex (1)

.126

.134

Age group

Odds 95.0% CI for odds ratio
ratio

Lower

Upper

.934

1.066

.231

4.931

1

.933

1.000

.992

1.009

.878

1

.349

1.134

.872

1.476

3.382

4

.496

Age Group (1)

.546

1.102

.245

1

.620

1.726

.199

14.956

Age Group (2)

.295

1.079

.075

1

.785

1.343

.162

11.140

Age Group (3)

.571

1.077

.281

1

.596

1.770

.214

14.628

Age Group (4)

.386

1.078

.128

1

.720

1.471

.178

12.170

3.921

3

.270

Race/ethnicity—Imputed
Race/ethnicity—Imputed (1)

-.318

.285

1.244

1

.265

.728

.416

1.272

Race/ethnicity—Imputed (2)

.382

.253

2.287

1

.130

1.466

.893

2.406

Race/ethnicity—Imputed (3)

-.126

.429

.087

1

.768

.881

.380

2.042

111.838

13

.000

Physician specialty—14 groups
Physician specialty—14 groups (1)

.110

.235

.218

1

.641

1.116

.705

1.767

Physician specialty—14 groups (2)

.099

.790

.016

1

.900

1.105

.235

5.197

Physician specialty—14 groups (3)

-1.115

.306

13.296

1

.000

.328

.180

.597

Physician specialty—14 groups (4)

-.458

.385

1.413

1

.235

.633

.298

1.346

Physician specialty—14 groups (5)

-1.626

.528

9.486

1

.002

.197

.070

.554

Physician specialty—14 groups (6)

-1.457

.478

9.288

1

.002

.233

.091

.594

Physician specialty—14 groups (7)

-2.831

.438

41.867

1

.000

.059

.025

.139

Physician specialty—14 groups (8)

-1.197

.254

22.177

1

.000

.302

.184

.497

Physician specialty—14 groups (9)

.822

.437

3.543

1

.060

2.275

.967

5.352

Physician specialty—14 groups (10)

-.203

.382

.281

1

.596

.817

.386

1.728

Physician specialty - 14 groups(11)

-2.779

.726

14.642

1

.000

.062

.015

.258

Physician specialty—14 groups (12)

-1.833

.477

14.781

1

.000

.160

.063

.407

Physician specialty—14 groups (13)

-.429

.187

5.274

1

.022

.651

.452

.939

12.084

3

.007

Region where majority of physician's
sampled visits occurred
Region where majority of physician's
sampled visits occurred (1)
Region where majority of physician's
sampled visits occurred (2)

.779

.239

10.599

1

.001

2.179

1.363

3.483

.478

.243

3.850

1

.050

1.612

1.001

2.598
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Region where majority of physician's
sampled visits occurred (3)
Constant
a

B

SE

Wald

df

Sig.

.662

.249

7.076

1

-3.509

1.121

9.804

1

Odds 95.0% CI for odds ratio
ratio

Lower

Upper

.008

1.939

1.190

3.160

.002

.030

Variable(s) entered on Step 1: Mental health provider seen, Time spent with physician in minutes, Patient sex, Age group,

Race/ethnicity—imputed, Physician specialty, Region where majority of physician's sampled visits occurred.

Summary
Chapter 4 used the NAMCS dataset, which comprises a national probability
sample of visits to the emergency and outpatient departments of noninstitutional general
and short-stay hospitals, to evaluate the predictors of depression screening in patients
diagnosed with cancer. The predictors included consultation with a mental health
professional, time spent with the physician, patient gender, age, and race, and physician
specialty. Even though the geographical region was not specified a priori as a predictor,
it was nevertheless included in the final analyses. It was included to characterize and
explore other potential predictors of depression screening among patients diagnosed with
cancer.
The results of the data analyses were presented in this chapter. Both univariate
and multivariate logistic regression were performed to characterize the predictors and
appropriately analyze the data. The odds ratios, including the CI and statistical
significance of the associations, were reported. Based on the simple logistic regression
analyses, age, physician specialty, and geographical region of physician visits were found
to be statistically significant predictors of receipt of depression screening among cancer
patients attending ambulatory care settings. The results of the multivariate analysis were
similar to those of the simple logistic regression analyses. However, when all the other
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independent variables were controlled for in the model, the gender variable was no longer
a statistically significant predictor of depression screening, thereby indicating a potential
confounding effect.
Chapter 5 will discuss the interpretation of the results and the strengths and
limitations of the study. The results will be discussed in the context of the current
knowledge in the discipline by comparing the findings in this study with those in the
recent literature . The chapter will end with recommendations for future research and the
positive social significance of the main results of this research work.
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Chapter 5: Discussion
Introduction
Cancer occurring comorbidly with depression continues to be a significant public
health problem (Pule et al., 2019). Despite improved cancer outcomes associated with
prompt and adequate treatment of depression in cancer, studies have shown that
depression is underrecognized and undertreated among cancer patients. Several
guidelines have recommended that cancer patients be routinely screened for depression.
Therefore, this research determined and evaluated the predictors of depression screening
among cancer patients in ambulatory care settings in the United States. The study
explored the factors that predict depression screening for cancer patients in ambulatory
settings. Sociodemographic factors, such as age, gender, and race, and other variables,
such as physician specialty, time spent with the physician, and consultation with a mental
health provider, were explored as potential predictor variables. The outcome variable was
depression screening (yes/no). The study used a quantitative approach with a crosssectional study design to determine if there were any relationships between the
independent and dependent variables. Secondary data from the NAMCS, which
comprises a national probability sample of visits to the emergency and outpatient
departments of noninstitutional general and short-stay hospitals, were analyzed.
The NAMCS data are designed to meet the need for objective, reliable
information about the provision and use of ambulatory medical care services in the
United States. The database is open to the public and easily accessed by going to a
website. The data were collected using surveys that captured physician-patient encounters
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or clinic visits. These encounters could have involved direct or personal interaction
between a patient and his or her physician or clinic staff working under the direct
supervision of a physician.
This study was conducted to contribute to the body of literature on depression
screening among cancer patients. My decision to conduct this study was based on the
public health significance of depression occurring comorbidly with cancer. Increased
knowledge of predictors of depression screening in cancer patients has the potential to
translate to a higher rate of screening, thereby reducing underdiagnosis and
undertreatment.
Interpretation of the Findings
This study is the first to explore the predictors of depression screening among
cancer patients. Findings from this research show that out of the total 7,146 visits that
met the inclusion criteria, 274 visits included depression screening. These data indicate
that among patients with cancer attending ambulatory care clinics during the entire study
period, approximately 3.8% of visits included depression screening. This shows that
depression screening of cancer patients in the United States is not very common. Other
key findings based on the simple logistic regression analyses in the current study were
that gender, physician specialty, and the geographic region in which physician visits
occurred were statistically significant predictors of receipt of depression screening among
cancer patients attending ambulatory care settings. The result of the multivariate analysis
was similar to the simple logistic regression. However, when the other independent
variables were controlled for, the gender variable was no longer a statistically significant
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predictor of depression screening, implying a potentially confounding effect.
The finding of a low depression screening rate among cancer patients in the
current study is similar to findings of previous studies that explored the rate of depression
screening among adults in ambulatory care settings in the United States (Bhattacharjee et
al., 2018; Harrison et al., 2010). Possible reasons for the low rate of depression screening
seen in the current study may be related to the evolution of guidelines and
recommendations for depression screening. There has been a highly contentious debate
on depression screening over the last three decades. Earlier recommendations had argued
against routine screening in the ambulatory care setting, with later updates in 2002 and
2009 recommending screening adults for depression only when appropriate staff-assisted
depression care supports are in place (USPSTF, 2002, 2009). Although the most recent
updates to the USPSTF recommendations on depression screeing in 2016 omitted the
requirement that screening only occur in the presence of enhanced services (Siu et al.,
2016), it is essential to note that the data analyzed in this study were 2014–2016 NAMCS
data. It is therefore possible that the previous restrictive guideline could have affected the
general rate of depression screening, which may explain the relatively low depression
screening rate reported in the current study.
Furthermore, uncertainty about the diagnosis of depression and subsequent
treatment could have contributed to the low rate of depression screening reported in the
current study. It is often challenging for physicians to differentiate between the “natural”
unhappiness and anxiety that accompany terminal illness diagnoses such as cancer and
pathological mood alterations. Complicating the uncertainty is the fact that it is not
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unusual for some of the symptoms of both conditions to overlap. Over time, most
healthcare providers dealing with comorbid conditions lose their self-efficacy about
treating cancer patients with depression. They lose the belief that such treatments can
make any difference in patient outcomes (Greenberg, 2004). Physicians often have
limited time for extensive discussion with their patients about any ongoing emotional and
psychological challenges. These limited interactions result in several missed
opportunities to elicit depressive symptoms from patients and create the right conditions
for physicians to avoid patients’ questions about emotions. Patients who are afraid of
being stigmatized also might refuse to volunteer information about their emotional
predicaments. The combination of a physician who refuses to “ask” and a patient who
refuses to “tell” makes depression screening very unlikely (Maguire, 1985).
Mental Health Provider
Both the simple logistic regression and the multivariable analysis did not detect
any significant predictive association between seeing a mental health provider during
visits and screening for depression. Qualified mental health providers play a pivotal role
in diagnosing depression and linking patients to treatment. Indeed, studies have shown
that depressed patients prefer that a mental health provider rather than a primary care
physician provide evidence-based treatment for their depression (Van Voorhees et al.,
2003). This implies that, contrary to this study's findings, one would expect that seeing a
mental health provider during an ambulatory visit would be a predictor of receiving
depression screening. One reason for the findings of the current study may be the low
proportion of visits in which mental health providers were seen, representing only 0.3%
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of the total visits included in the study. In essence, the result should not necessarily be
interpreted as meaning that the mental health services offered by mental health providers
are meaningless, but rather that there were insufficient visits with mental health providers
to demonstrate any relationship. In the current study, out of the 7,146 visits included in
the analysis, only 20 visits included visits to mental health providers. The
disproportionately low number of visits with mental health providers may explain why
there was no association between visits to a mental health provider and screening for
depression.
Time Spent With Physician
Furthermore, time spent with the physician was not a significant predictor of
depression screening. This may underscore the importance of differentiating between
quality versus quantity of time spent with the physician. This finding implies that
increasing the length of visits to a physician’s office does not necessarily substitute for a
qualitative physician office visit. Complex and dynamic physician-patient interactions,
including time spent gathering a patient’s history, establishing a relationship, and
engaging in administrative work, contribute to the time that a physician spends with
patients (Dugdale et al., 1999). Typically, the physician’s workload does not allow
enough time to navigate all of these complex interactions. Therefore, even when the time
for physician-patient interaction increases, there are multiple activities that may occur
during this time, and screening for depression is not necessarily among them.
Gender
This study found that females were more likely to be screened for depression than
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males in the simple logistic regression analysis. This was in keeping with a higher
incidence of depression among females in the general population. However, some
prevalence research studies on gender differences in cancer occurring comorbidly with
depression have, for the most part, yielded conflicting results (Miaskowski, 2004). For
example, some studies have found that the gender difference in the depression incidence
rate among the general population is reversed among cancer patients, with depression
occurring more in men, and men with cancer reporting more depression symptoms than
women with cancer (Pudrovska, 2010). Other investigators have reported that depressed
women are more likely than depressed men to present with psychiatric and medical
comorbidity, including cancer (de Leeuw et al., 2001; Hopwood & Stephens, 2000; Sloan
& Sandt, 2006). The finding that females demonstrated significantly higher odds of
depression screening than their male counterparts is similar to previous studies
(Bhattacharjee et al., 2018; Harrison et al., 2010). This variation may well imply that the
lower prevalence rates of depression seen in male cancer patients may be driven by
underdiagnosis due to a lower screening rate.
This finding underscores the importance of driving awareness campaigns and
educating male cancer patients about depression, screening for depression, and
engagement in early treatment as appropriate. This is particularly important in that cancer
has more adverse psychological implications for men than for women (Pudrovska, 2010).
Physicians should also be aware of the need to actively pursue depression screening for
male cancer patients.
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Age
Although studies have shown that depression tends to vary with age, this study
showed that age did not significantly predict depression screening among cancer patients.
The result showing that age was not a significant predictor of depression screening
among cancer patients was the same for the multivariable analysis. While studies have
shown that cancer and mental health comorbidities are associated with poorer outcomes,
studies have also shown that the age of patients with comorbidities is not a driver of
poorer outcomes and not a predictor of clinical response (Angstman et al., 2011). This
may explain why age was not a significant predictor of depression screening among the
patient population. If age is not related to patient outcome, then there may not be any
motivation to screen patients for depression based on their age alone.
Race
Concerning the fifth research question, results showed that race was not a
significant predictor of screening for depression among cancer patients. Based on the data
analyzed, the total sample of those screened for depression across the different racial
groups was small. Additionally, there was disproportionate representation of the different
racial groups in the study, with non-Hispanic Whites heavily and disproportionately
represented compared to the other racial groups. This may have been responsible for the
nonsignificant association found in the data.
Region
The current study demonstrated that cancer patients who had physician visits in
the Northeast region were more likely to be screened for depression than those having
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physician visits in the other geographic regions of the United States. This finding is in
keeping with previous research (Bhattacharjee et al., 2018; Harrison et al., 2010). This
may be a result of disparities in the physician workforce across the country. Based on the
current projection, the South and West regions are expected to continue to see more
physician workforce shortages than the Northeast (Zhang et al., 2020). Other reasons for
these findings may involve the geographic distribution of physicians across the four U.S.
Census Bureau regions. Residents of metropolitan areas such as those of the Northeast
have better geographic access to physicians, whereas residents of isolated rural counties
have less access (Rosenthal et al., 2005). This research underscores the need to create
enabling environments that can improve the awareness of depression screening,
especially in regions outside the Northeast.
Physician Specialty
The current study showed that the odds of screening for depression were
significantly higher during a visit to a primary care physician than to physicians of other
specialties. Different guidelines recommend that the general adult population be screened
for depression with the primary care physician designated as the primary focus for
screening for depression. For example, the American College of Preventive Medicine
(ACPM) emphasizes the primary care physician as the care provider to screen for
depression. Specifically, the ACPM recommends that the primary care physician screen
all adults for depression, and that there should be systems in place, either within the
primary care setting itself or through collaborations with mental health professionals, to
ensure the accurate diagnosis and treatment of depression (Nimalasuriya et al., 2009).
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As a generalization, most patients with depression, including cancer patients with
comorbid depression, will receive their depression care in the primary care setting. There
is evidence that patients with comorbid depression are more likely to contact a primary
care provider than providers in other specialties (Akincigil & Matthews, 2017). This
study’s results go further to emphasize the pivotal role that primary care physicians play
in ensuring prompt diagnosis and adequate follow-up treatment for cancer patients with
depression. Lo and colleagues (2013) explored how depression affected health care
service utilization in patients diagnosed with cancer. They reported that patients with
depression were more likely to visit primary care physicians but less likely to visit
oncologists than cancer patients without depression (Lo et al., 2013). Therefore, all
efforts must be made to ensure that primary care physicians continue to have all they
require to continue to provide depression screening for the cancer population.
Limitations
The current study had some limitations, and as a result, findings from this
research work should be interpreted with caution. First, this study's cross-sectional design
implies that both the predictors and the outcome variable were simultaneously assessed
and does not allow for causal inference. Further, the fact that a patient was not screened
for depression during a particular visit does not mean that the patient was not screened by
some other means. Additionally, the dataset did not identify any specific depression
screening type or procedure used by physicians. This makes it difficult to understand how
the different physicians defined depression screening. The implication is that depression
screening methods may have varied widely from one physician to another. While some
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providers may have adopted a particular type of screening criteria, others may have used
different screening criteria.
Another limitation of the current study related to the NAMCS data is that
depression screening was explored based on patient visits. It is quite possible that
different estimates might have been derived if the predictors of depression screening had
been explored using individual patients as the unit of analysis instead of physician visits.
The relatively low proportion of some of the variables may mean that there were not
enough data to demonstrate whether there was any effect. For example, the proportion of
visits that included seeing a mental health provider was very low. While there was no
significant relationship between seeing a mental health provider and depression
screening, it is difficult to conclude that the services provided by the mental health
providers were not clinically significant. Finally, given that secondary data were used, it
is not possible to conveniently rule out potential data collection errors, data entry errors,
and data reporting errors.
Recommendations
In the current study, I focused primarily on the predictors of depression screening
among cancer patients. There were a number of reasons for this focus, including the
dearth of literature in the field of predictors of depression screening among cancer
patients, the public health significance of depression occurring comorbidly with cancer,
and the potential that the knowledge of predictors of depression screening in cancer
patients may translate to a higher rate of screening, thereby reducing underdiagnosis and
undertreatment. As mentioned above, this study used a cross-sectional design, which

105
precludes the possibility of making any causal inference. Future research should use other
study designs where patients are followed up until the desired outcome of interest is
observed or not observed. This type of study design can better establish a causal
relationship. The NAMCS dataset used in this research did not specify the strategy used
for depression screening; therefore, future research should improve on this by defining
and standardizing depression screening methods across all patients and physician visits.
Future research should also use patients as the unit of analysis rather than physician
visits.
Furthermore, in the current study, I explored the predictors of depression
screening among cancer patients in general. Potentially, different cancer types, including
anatomic location and histology, may have different predictors for depression screening..
Therefore, future studies should seek to explore the predictors of depression screening in
different cancer types.
Implications
The results of the current study can potentially influence positive social change at
both the individual and organizational levels. The findings can also inform policy
changes that can impact screening guidelines at the societal level. From the study, gender
was a predictor of screening for depression among cancer patients, with females having a
higher probability of being screened. This knowledge presents an opportunity for a
targeted educational strategy among male cancer patients to increase the awareness of
depression co-occurring with cancer and engage their physicians on the need to screen
proactively.
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Additionally, this research showed that a visit to a primary care physician is more
likely to result in screening for depression among cancer patients compared to other
physician specialists. This is in keeping with most guidelines for depression screening in
which primary care physicians are the primary drivers of depression screening. While the
current study can encourage the continuous provision of incentives to strengthen
proactive screening for depression among cancer patients by primary care physicians,
guidelines and policies can be updated to ensure proper training for other specialists to
reduce the many missed opportunities for depression screening. Overall, the current study
can contribute to society by stimulating new approaches to recognizing and managing
patients with comorbid conditions and informing public debates, policy-making
strategies, and screening guidelines.
Conclusion
The current study explored the predictors of depression screening among cancer
patients in the ambulatory care setting in the United States. While depression screening is
a crucial first step in diagnosing depression among cancer patients and connecting
patients to the treatment they need, the current study found that the depression screening
rate among cancer patients is extremely low in the U.S ambulatory care setting (3.8%).
The current study found patient gender, physician specialty, and geographic region to be
statistically significant predictors of depression screening among cancer patients. Based
on these findings, routine depression screening rates among cancer patients can be
improved by targeting interventions, especially at male patients, and improving
physicians' training so they can gain competence in screening for depression. The results
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also suggest an opportunity for creating an enabling environment that can enhance the
awareness of depression screening in the West, South, and Midwest geographic region of
the U.S.
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